



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07K 14/195, C12P 21/06, C07H 17/00	A1	(11) International Publication Number: WO 96/11947 (43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: PCT/US95/13023 (22) International Filing Date: 13 October 1995 (13.10.95) (30) Priority Data: 322,760 13 October 1994 (13.10.94) US (71)(72) Applicant and Inventor: GOLDBERG, Edward, B. [US/US]; 494 Ward Street, Newton, MA 02159-1136 (US). (74) Agents: MORRIS, Francis, E. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>
(54) Title: MATERIALS FOR THE PRODUCTION OF NANOMETER STRUCTURES AND USE THEREOF (57) Abstract The present invention pertains to nanostructures, i.e., nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**MATERIALS FOR THE PRODUCTION OF
NANOMETER STRUCTURES AND USE THEREOF**

FIELD OF THE INVENTION

5 The present invention pertains to nanostructures, i.e., nanometer sized structures useful in the construction of microscopic and macroscopic structures. In particular, the present invention pertains to nanostructures based on bacteriophage T4 tail fiber proteins and variants thereof.

10 **BACKGROUND TO THE INVENTION**

 While the strength of most metallic and ceramic based materials derives from the theoretical bonding strengths between their component molecules and crystallite surfaces, it is significantly limited by flaws in their
15 crystal or glass-like structures. These flaws are usually inherent in the raw materials themselves or developed during fabrication and are often expanded due to exposure to environmental stresses.

20 The emerging field of nanotechnology has made the limitations of traditional materials more critical. The ability to design and produce very small structures (i.e., of nanometer dimensions) that can serve complex functions depends upon the use of appropriate materials that can be
25 manipulated in predictable and reproducible ways, and that have the properties required for each novel application.

 Biological systems serve as a paradigm for sophisticated nanostructures. Living cells fabricate proteins and combine them into structures that are perfectly formed
30 and can resist damage in their normal environment. In some cases, intricate structures are created by a process of self-assembly, the instructions for which are built into the component polypeptides. Finally, proteins are subject to proofreading processes that insure a high degree of quality
35 control.

 Therefore, there is a need in the art for methods and compositions that exploit these unique features of

proteins to form constituents of synthetic nanostructures. The need is to design materials whose properties can be tailored to suit the particular requirements of nanometer-scale technology. Moreover, since the subunits of
5 most macrostructural materials, ceramics, metals, fibers, etc., are based on the bonding of nanostructural subunits, the fabrication of appropriate subunits without flaws and of exact dimensions and uniformity should improve the strength and consistency of the macrostructures because the surfaces
10 are more regular and can interact more closely over an extended area than larger, more heterogeneous material.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides
15 isolated protein building blocks for nanostructures, comprising modified tail fiber proteins of bacteriophage T4. The gp34, 36, and 37 proteins are modified in various ways to form novel rod structures with different properties. Specific internal peptide sequences may be deleted without
20 affecting their ability to form dimers and associate with their natural tail fiber partners. Alternatively, they may be modified so that they: interact only with other modified, and not native, tail fiber partners; exhibit thermolabile interactions with their partners; or contain additional
25 functional groups that enable them to interact with heterologous binding moieties.

The present invention also encompasses fusion proteins that contain sequences from two or more different tail fiber proteins. The gp35 protein, which forms an angle
30 joint, is modified so as to form average angles different from the natural average angle of $137^\circ (\pm 7^\circ)$ or $156^\circ (\pm 12^\circ)$, and to exhibit thermolabile interactions with its partners.

In another aspect, the present invention provides nanostructures comprising native and modified tail fiber
35 proteins of bacteriophage T4. The nanostructures may be one-dimensional rods, two-dimensional polygons or open or closed sheets, or three-dimensional open cages or closed solids.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B show a schematic representation of the T4 bacteriophage particle (Figure 1A), and a schematic representation of the T4 bacteriophage tail fiber (Figure 5 1B).

Figure 2 shows a schematic representation of a unit rod.

Figures 3A-3D show schematic representations of: a one-dimensional multi-unit rod joined along the x axis 10 (Figure 3A); closed simple sheets (Figure 3B); closed brickwork sheets (Figure 3C); and open brickwork sheets (Figure 3D).

Figure 4 shows a schematic representation of two units used to construct porous and solid sheets (top and 15 bottom), which, when alternatively layered, produce a multi-tiered set of cages as shown.

Figure 5 shows a schematic representation of an angled structure having an angle of 120°.

Figure 6 shows the DNA sequence (SEQ ID NO:1) of 20 genes 34, 35, 36, and 37 of bacteriophage T4.

Figure 7 shows the amino acid sequences (shown in single-letter codes) of the gene products of genes 34 (SEQ ID NO:2, ORFX SEQ ID NO:3), 35 (SEQ ID NO:4), 36 (SEQ ID NO:5), and 37 (SEQ ID NO:6) of bacteriophage T4. The 25 amino acid sequences (bottom line of each pair) are aligned with the nucleotide sequences (top line of each pair.) It is noted that the deduced protein sequence of gene 35 (from NCBI database) is not believed to be accurate.

Figures 8A-8B show a schematic representation of: 30 the formation of a P37 dimer initiator from a molecule that self-assembles into a dimer (Figure 8A); and the formation of a P37 trimer initiator from a molecule that self-assembles into a trimer (Figure 8B).

Figure 9 shows a schematic representation of the 35 formation of the polymer (P37-36)_n with an initiator that is a self-assembling dimer.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications and literature references cited in the specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including, definitions, will prevail.

Although the invention is described in terms of bacteriophage T4 tail fiber proteins, it will be understood that the invention is also applicable to tail fiber proteins of other T-even-like phage, e.g., of the T4 family (e.g., T4, TuIa, TuIb), and T2 family (T2, T6, K3, Ox2, M1, etc.)

DEFINITIONS:

"Nanostructures" are defined herein as structures of different sizes and shapes that are assembled from nanometer-sized protein components.

"Chimers" are defined herein as chimeric proteins in which at least the amino- and carboxy-terminal regions are derived from different original polypeptides, whether the original polypeptides are naturally occurring or have been modified by mutagenesis.

"Homodimers" are defined herein as assemblies of two substantially identical protein subunits that form a defined three-dimensional structure.

The designation "gp" denotes a monomeric polypeptide, while the designation "P" denotes homooligomers. P34, P36, and P37 are presumably homodimers or homotrimers.

An isolated polypeptide that "consists essentially of" a specified amino acid sequence is defined herein as a polypeptide having the specified sequence or a polypeptide that contains conservative substitutions within that sequence. Conservative substitutions, as those of ordinary skill in the art would understand, are ones in which an acidic residue is replaced by an acidic residue, a basic residue by a basic residue, or a hydrophobic residue by a hydrophobic residue. Also encompassed is a polypeptide that lacks one or more amino acids at either the amino terminus or

carboxy terminus, up to a total of five at either terminus, when the absence of the particular residues has no discernable effect on the structure or the function of the polypeptide in practicing the present invention.

5 The present invention pertains to a new class of protein building blocks whose dimensions are measured in nanometers, which are useful in the construction of microscopic and macroscopic structures. Without wishing to be bound by theory, it is believed that the basic unit is a
10 homodimer composed of two identical protein subunits having a cross- β configuration, although a trimeric structure is also possible. Thus, as will be apparent, references to a "homodimer" or "dimerization" as used herein will in many instances be construed as also referring to a homotrimer or
15 trimerization. These long, stiff, and stable rod-shaped units can assemble with other rods using coupling devices that can be attached genetically or *in vitro*. The ends of one rod may attach to different ends of other rods or similar rods. Variations in the length of the rods, in the angles of
20 attachment, and in their flexibility characteristics permit differently-shaped structures to self-assemble *in situ*. In this manner the units can self-assemble into predetermined larger structures of one, two or three dimensions. The self-assembly can be staged to form structures of precise
25 dimensions and uniform strength due to the flawless biological manufacture of the components. The rods can also be modified by genetic and chemical modifications to form predetermined specific attachment sites for other chemical entities, allowing the formation of complex structures.

30 An important aspect of the present invention is that the protein units can be designed so that they comprise rods of different lengths, and can be further modified to include features that alter their surface properties in predetermined ways and/or influence their ability to join
35 with other identical or different units. Furthermore, the self-assembly capabilities can be expanded by producing chimeric proteins that combine the properties of two

different members of this class. This design feature is achieved by manipulating the structure of the genes encoding these proteins.

As detailed below, the compositions and methods of the present invention take advantage of the properties of the natural proteins, i.e., the resulting structures are stiff, strong, stable in aqueous media, heat resistant, protease resistant, and can be rendered biodegradable. A large quantity of units can be fabricated easily in microorganisms. Furthermore, for ease of automation, large quantities of parts and subassemblies can be stored and used as needed.

The sequences of the protein subunits are based on the components of the tail fiber of the T4 bacteriophage of *E. coli*. It will be understood that the principles and techniques can be applied to the tail fibers of other T-even phages, or other related bacteriophages that have similar tail and/or fiber structures.

The structure of the T4 bacteriophage tail fiber (illustrated in Figure 1) can be represented schematically as follows (N= amino terminus, C= carboxy terminus): N[P34]C - N[gp35]C - N[P36]C - N[P37]C. P34, P36, and P37 are all stiff, rod-shaped protein homodimers in which two identical β sheets, oriented in the same direction, are fused face-to-face by hydrophobic interactions between the sheets juxtaposed with a 180° rotational axis of symmetry through the long axis of the rod. (The structure will vary if P34, P36, and P37 are homotrimers.) gp35, by contrast, is a monomeric polypeptide that attaches specifically to the N-terminus of P36 and then to the C-terminus of P34 and forms an angle joint between two rods. During T4 infection of *E. coli*, two gp37 monomers dimerize to form a P37 homodimer; the process of dimerization is believed to initiate near the C-terminus of P37 and to require two *E. coli* chaperon proteins. (A variant gp37 with a temperature sensitive mutation near the C-terminus used in the present invention requires only one chaperon, gp57, for dimerization.) Once dimerized, the N-terminus of P37 initiates the dimerization

of two gp36 monomers to a P36 rod. The joint between the C-terminus of P36 and the N-terminus of P37 is tight and stiff but noncovalent. The N-terminus of P36 then attaches to a gp35 monomer; this interaction stabilizes P36 and forms the elbow of the tail fiber. Finally, gp35 attaches to the C-terminus of P34 (which uses gp57 for dimerization). Thus, self assembly of the tail fiber is regulated by a predetermined order of interaction of specific subunits whereby structural maturation caused by formation of the first subassembly permits interaction with new (previously disallowed) subunits. This results in the production of a structure of exact specifications from a random mixture of the components.

In accordance with the present invention, the genes encoding these proteins may be modified so as to make rods of different lengths with different combinations of ends. The properties of the native proteins are particularly advantageous in this regard. First, the β -sheet is composed of antiparallel β -strands with β -bends at the left (L) and right (R) edges. Second, the amino acid side chains alternate up and down out of the plane of the sheet. The first property allows bends to be extended to form symmetric and specific attachment sites between the L and R surfaces, as well as to form attachment sites for other structures. In addition, the core sections of the β -sheet can be shortened or lengthened by genetic manipulations e.g., by splicing DNA regions encoding β -bends, on the same edge of the sheet, to form new bends that exclude intervening peptides, or by inserting segments of peptide in an analogous manner by splicing at bend angles. The second property allows amino acid side chains extending above and below the surface of the β -sheet to be modified by genetic substitution or chemical coupling. Importantly, all of the above modifications are achieved without compromising the structural integrity of the rod. It will be understood by one skilled in the art that these properties allow a great deal of flexibility in

designing units that can assemble into a broad variety of structures, some of which are detailed below.

STRUCTURAL UNITS

5 The rods of the present invention function like wooden 2 X 4 studs or steel beams for construction. In this case, the surfaces are exactly reproducible at the molecular level and thereby fitted for specific attachments to similar or different units rods at fixed joining sites. The surfaces
10 are also modified to be more or less hydrophilic, including positively or negatively charged groups, and have protrusions built in for specific binding to other units or to an intermediate joint with two receptor sites. The surfaces of the rod and a schematic of the unit rod are illustrated in
15 Figure 2. The three dimensions of the rod are defined as: x, for the back (B) to front (F) dimension; y, for the down (D) to up (U) dimension; and z, for the left (L) to right (R) dimension.

One dimensional multi-unit rods can be most readily
20 assembled from single unit rods joined along the x axis (Figure 3A) but regular joining of subunits in either of the other two dimensions will also form a long structure, but with different cross sections than in the x dimension.

Two dimensional constructs are sheets formed by
25 interaction of rods along any two axes. 1) Closed simple sheets are formed from surfaces which overlap exactly, along any two axes (Figure 3B). 2) Closed brickwork sheets are formed from interaction between units that have exactly overlapping surfaces in one dimension and a special type of
30 overlap in the other (Figure 3C). In this case there must be two different sets of complementary joints spaced with exactly 1/2 unit distance between them. If they are centered (i.e., each set 1/4 from the end) then each joint will be in the center of the units above and below. If they are offset,
35 then the joint will be offset as well. In this construction, the complementary interacting sites are schematized by * and **. If the interacting sites are each symmetric, the

alternating rows can interact with the rods in either direction. If they are not symmetric, and can only interact with interacting rows facing in the same or opposite direction, the sheet will be made of unidirectional rods or
5 layers of rods in alternating directions. 3) Open brickwork sheets (or nets) result when the units are separated by more than one-half unit (Figure 3D). The dimensions of the openings (or pores) depend upon the distance (dx) separating the interacting sites and the distance (dy) by which these
10 sites separate the surfaces.

Three dimensional constructs require sterically compatible interactions between all three surfaces to form solids. 1) Closed solids can assemble from units that overlap exactly in all three dimensions (e.g., the exact
15 overlapping of closed simple sheets). In an analogous manner, closed brickwork sheets can form closed solids by overlapping sheets exactly or displaced to bring the brickwork into the third dimension. This requires an appropriate set of joints on all three pairs of parallel
20 faces of the unit. 2) Porous solids are made by joining open brickwork sheets in various ways. For example, if the units overlap exactly in the third dimension, a solid is formed with the array of holes of exact dimensions running perpendicular to the plane of the paper. If instead, a
25 material is needed with closed spaces, with layers of width dz (i.e., in the U→D dimension), a simple closed sheet is layered on the open brickwork sheet to close the openings. If the overlap of the open brickwork sheet is e.g., 1/4 unit, then a rod of length 3/4 units is used to make the sheet.
30 Joints are then needed in the z dimension. The two units used to polymerize these alternate layers, and the layers themselves, are schematized in Figure 4.

All of the above structures are composed of simple linear rods. A second unit, the angle unit, expands the type
35 and dimensionality of possible structures. The angle unit connects two rods at angles different from 180°, akin to an angle iron. The average angle and its degree of rigidity are

built into this connector structure. For example, the structure shown in Figure 5 has an angle of 120° and different specific joining sites at a and at b. The following are examples of structures that are formed
5 utilizing angle joints:

1) Open brickwork sheets are expanded and strengthened in the direction normal to the rod direction by adding angles perpendicular to the sheet. In this case, a three dimensional network forms. Attachment of 90° angles to
10 the ends of the rods makes an angle almost in the plane of the sheet, allowing new rods added to those angles (which must have some play out of the plane of the original sheet to attach in the first place) to form a new sheet, almost parallel, with an orientation normal to its upper or lower
15 neighbor.

2) Hexagons are made from a mixture of rods and angle joints that form 120° angles. In this case, there are two exclusive sets of joints. Each set is made up of one of the two ends of the rod and one of the two complementary
20 sites on the angle. This is a linear structure in the sense that the hexagon has a direction (either clockwise or counterclockwise). It can be made into a two dimensional open net (i.e., a two dimensional honeycomb) by joining the sides of the hexagons. It can form hexagonal tubes by
25 joining the top of the hexagon below to the bottom face of the hexagon above. If the tubes also join by their sides, they will form an open three dimensional multiple hexagonal tube.

3) Helical hexagonal tubes are made analogously to
30 hexagons but the sixth unit is not joined to the first to close the hexagon. Instead, the end is displaced from the plane of the hexagon and the seventh and further units are added to form a hexagonal tube which can be a spring if there is little or no adhesive force between the units of the
35 helix, or a stiff rod if there is such a force to maintain the close proximity of apposing units.

It will be apparent to one skilled in the art that the compositions and methods of the present invention also encompass other polygonal structures such as octagons, as well as open solids such as tetrahedrons and icosahedrons formed from triangles and boxes formed from squares and rectangles. The range of structures is limited only by the types of angle units and the substituents that can be engineered on the different axes of the rod units. For example, other naturally occurring angles are found in the fibers of bacteriophage T7, which has a 90° angle (Steven et al., *J. Mol. Biol.* 200: 352-365, 1988).

DESIGN AND PRODUCTION OF THE ROD PROTEINS

The protein subunits that are used to construct the nanostructures of the present invention are based on the four polypeptides that comprise the tail fibers of bacteriophage T4, i.e., gp34, gp35, gp36 and gp37. The genes encoding these proteins have been cloned, and their DNA and protein sequences have been determined (for gene 36 and 37 see Oliver et al. *J. Mol. Biol.* 153: 545-568, 1981). The DNA and amino acid sequences of genes 34, 35, 36 and 37 are set forth in Figures 6 and 7 below.

Gp34, gp35, gp36, and gp37 are produced naturally following infection of *E. coli* cells by intact T4 phage particles. Following synthesis in the cytoplasm of the bacterial cell, the gp34, 36, and 37 monomers form homodimers, which are competent for assembly into maturing phage particles. Thus, *E. coli* serves as an efficient and convenient factory for synthesis and dimerization of the protein subunits described herein below.

In practicing the present invention, the genes encoding the proteins of interest (native, modified, or recombinant) are incorporated into DNA expression vectors that are well known in the art. These circular plasmids typically contain selectable marker genes (usually conferring antibiotic resistance to transformed bacteria), sequences that allow replication of the plasmid to high copy number in

E. coli, and a multiple cloning site immediately downstream of an inducible promoter and ribosome binding site. Examples of commercially available vectors suitable for use in the present invention include the pET system (Novagen, Inc.,
5 Madison, WI) and Superlinker vectors pSE280 and pSE380 (Invitrogen, San Diego, CA).

The strategy is to 1) construct the gene of interest and clone it into the multiple cloning site; 2) transform *E. coli* cells with the recombinant plasmid; 3)
10 induce the expression of the cloned gene; 4) test for synthesis of the protein product; and, finally, 5) test for the formation of functional homodimers. In some cases, additional genes are also cloned into the same plasmid, when their function is required for dimerization of the protein of
15 interest. For example, when wild-type or modified versions of gp37 are expressed, the bacterial chaperon gene 57 is also included; when wild-type or modified gp36 is expressed, the wild-type version or a modified version of the gp37 gene is included. The modified gp37 should have the capacity to
20 dimerize and contain an N-terminus that can chaperon the dimerization of gp36. This method allows the formation of monomeric gene products and, in some cases, maturation of monomers to homodimeric rods in the absence of other phage-induced proteins normally present in a T4-infected
25 cell.

Steps 1-4 of the above-defined strategy are achieved by methods that are well known in the art of recombinant DNA technology and protein expression in bacteria. For example, in step 1, restriction enzyme
30 cleavage at multiple sites, followed by ligation of fragments, is used to construct deletions in the internal rod segment of gp34, 36, and 37 (see Example 1 below). Alternatively, a single or multiple restriction enzyme cleavage, followed by exonuclease digestion (EXO-SIZE, New
35 England Biolabs, Beverly, MA), is used to delete DNA sequences in one or both directions from the initial cleavage site; when combined with a subsequent ligation step, this

procedure produces a nested set of deletions of increasing size. Similarly, standard methods are used to recombine DNA segments from two different tail fiber genes, to produce chimeric genes encoding fusion proteins (called "chimera" in this description). In general, this last method is used to provide alternate N- or C-termini and thus create novel combinations of ends that enable new patterns of joining of different rod segments. A representative of this type of chimera, the fusion of gp37-36, is described in Example 2.

10 The preferred hosts for production of these proteins (Step 2) is *E. coli* strain BL21(DE3) and BL21(DE3/pLysS) (available commercially from Novagen, Madison, WI), although other compatible *recA* strains, such as HMS174(DE3) and HMS174(DE3/pLysS) can be used. Transformation with the

15 recombinant plasmid (Step 2) is accomplished by standard methods (Sambrook, J., *Molecular Cloning*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY; this is also the source for standard recombinant DNA methods used in this invention.) Transformed bacteria are selected by virtue of their

20 resistance to antibiotics e.g., ampicillin or kanamycin. The method by which expression of the cloned tail fiber genes is induced (Step 3) depends upon the particular promoter used. A preferred promoter is *plac* (with a *lacI^q* on the vector to reduce background expression), which can be regulated by the

25 addition of isopropylthiogalactoside (IPTG). A second preferred promoter is pT7 ϕ 10, which is specific to T7 RNA polymerase and is not recognized by *E. coli* RNA polymerase. T7 RNA polymerase, which is resistant to rifamycin, is encoded on the defective lambda DE lysogen in the *E. coli*

30 BL21 chromosome. T7 polymerase in BL21(DE3) is super-repressed by the *lacI^q* gene in the plasmid and is induced and regulated by IPTG.

Typically, a culture of transformed bacteria is incubated with the inducer for a period of hours, during

35 which the synthesis of the protein of interest is monitored. In the present instance, extracts of the bacterial cells are

prepared, and the T4 tail fiber proteins are detected, for example, by SDS-polyacrylamide gel electrophoresis.

Once the modified protein is detected in bacterial extracts, it is necessary to ascertain whether or not it forms appropriate homodimers (Step 4). This is accomplished initially by testing whether the protein is recognized by an antiserum specific to the mature dimerized form of the protein.

Tail fiber-specific antisera are prepared as described (Edgar, R.S. and Lielausis, I., *Genetics* 52: 1187, 1965; Ward et al, *J. Mol. Biol.* 54:15, 1970). Briefly, whole T4 phage are used as an immunogen; optionally, the resulting antiserum is then adsorbed with tail-less phage particles, thus removing all antibodies except those directed against the tail fiber proteins. In a subsequent step, different aliquots of the antiserum are adsorbed individually with extracts that each lack a particular tail fiber protein. For example, if an extract containing only tail fiber components P34, gp35, and gp36 (derived from a cell infected with a mutant T4 lacking a functional gp37 gene) is used for absorption, the resulting antiserum will recognize only mature P37 and dimerized P36-P37. A similar approach may be used to prepare individual antisera that recognize only mature (i.e., homodimerized) P34 and P36 by adsorbing with extracts containing distal half tail fibers or P34, gp35 and P37, respectively. An alternative is to raise antibody against purified tail fiber halves, e.g., P34 and gp35-P36-P37. Anti gp35-P36-P37 can then be adsorbed with P36-P37 to produce anti-gp35, and anti-P36 can be produced by adsorption with P37 and gp35. Anti-P37, anti-gp35, and anti-P34 can also be produced directly by using purified P37, gp35, and P34 as immunogens. Another approach is to raise specific monoclonal antibodies against the different tail fiber components or segments thereof.

Specific antibodies to subunits or tail parts are used in any of the following ways to detect appropriately homodimerized tail fiber proteins: 1) Bacterial colonies are

screened for those expressing mature tail fiber proteins by directly transferring the colonies, or, alternatively, samples of lysed or unlysed cultures, to nitrocellulose filters, lysing the bacterial cells on the filter if necessary, and incubating with specific antibodies. Formation of immune complexes is then detected by methods widely used in the art (e.g., secondary antibody conjugated to a chromogenic enzyme or radiolabelled Staphylococcal Protein A.). This method is particularly useful to screen large numbers of colonies e.g., those produced by EXO-SIZE deletion as described above. 2) Bacterial cells expressing the protein of interest are first metabolically labelled with ³⁵S-methionine, followed by preparation of extracts and incubation with the antiserum. The immune complexes are then recovered by incubation with immobilized Protein A followed by centrifugation, after which they may be resolved by SDS-polyacrylamide gel electrophoresis.

An alternative competitive assay for testing whether internally deleted tail fiber proteins that do not permit phage infection nonetheless retain the ability to dimerize and associate with their appropriate partners utilizes an *in vitro*, complementation system. 1) A bacterial extract containing the modified protein of interest, as described above, is mixed with a second extract prepared from cells infected with a T4 phage that is mutant in the gene of interest. 2) After several hours of incubation, a third extract is added that contains the wild-type version of the protein being tested, and incubation is continued for several additional hours. 3) Finally, the extract is titered for infectious phage particles by infecting *E. coli* and quantifying the phage plaques that result. A modified tail fiber protein that is correctly dimerized and able to join with its partners is incorporated into tail fibers in a non-functional manner in Step 1, thereby preventing the incorporation of the wild-type version of the protein in Step 2; the result is a reduction in the titer of the resulting phage sample. By contrast, if the modified protein is unable

to dimerize and thus form proper N- and/or C-termini, it will not be incorporated into phage particles in Step 1, and thus will not compete with assembly of intact phage particles in Step 2; the phage titer should thus be equivalent to that observed when no modified protein is added in Step 1 (a negative control.)

Another way in which to test whether chimeras and internally deleted tail fiber proteins retain the ability to dimerize and associate with their appropriate partners is done *in vivo*. The assay detects the ability of such chimeras and deleted proteins to compete with normal phage parts for assembly, thus reducing the burst size of a wild-type phage infecting the same host cell in which the chimeras or deleted proteins are recombinantly expressed. Thus, expression from an expression vector encoding the chimera or deleted protein is induced inside a cell, which cell is then infected by a wild-type phage. Inhibition of wild-type phage production demonstrates the ability of the recombinant chimera or protein to associate with the appropriate tail fiber proteins of the phage.

The above-described methods are used, alone and in combination, in the design and production of different types of modified tail fiber proteins. For example, a preliminary screen of a large number of bacterial colonies for those expressing a properly dimerized protein will identify positive colonies, which can then be individually tested by *in vitro* complementation.

Non-limiting examples of novel proteins that are encompassed by the present invention include:

- 1) Internally deleted gp34, 36, and 37 polypeptides (See Example 1 below);
- 2) A C-terminally truncated gp36 fused to the N-terminus of N-terminally truncated gp37;
- 3) A fusion between gp36 and gp37 in which gp37 is N-terminal to gp36 (*i.e.*, in reverse of the natural order), termed here in "gp37-36 chimera" (See Example 2 below);

4) A fusion between gp34 and gp36 in which gp36 is N-terminal to gp34 (i. e., in reverse of the natural order), termed herein "gp36-34 chimer";

5) A variant of gp36 in which the C-terminus is mutated such that it lacks the capability to interact with (and dimerize in response to) the N-terminus of wild-type P37, termed herein "gp36*";

6) A variant of gp37 in which the N-terminus is mutated such that it forms a P37 that lacks the capability to interact with the C-terminus of wild-type gp36, termed herein "*P37";

7) Variants of gp36* and *P37 that can interact with each other, but not with gp36 or P37.

8) A variant "P37-36 chimer" in which the gp36 moiety is derived from the variant as in 5), i.e., "P37-36*". (For 5-8, See Example 3 below.)

9) A variant "P37-36 chimer" in which the gp37 moiety is derived from the variant as in 6) above, i.e., "*P37-36".

10) A variant P37-36 chimer, *P37-P36*, in which the gp36 and gp37 moieties are derived from the variants in 7).

11) A fusion between gp36 and gp34 in which gp36 sequences are placed N-terminal to gp34, the dimer of which is termed herein "P36-34 chimer";

12) Variants of gp35 that form average angles different from 137° or 158° (the native angle) e.g., less than about 125° or more than about 145° under conditions wherein the wild-type gp35 protein forms an angle of 137° when combined with the P34 and P36-P37 dimers, and/or exhibit more or less flexibility than the native polypeptide;

13) Variants of gp34, 35, 36 and 37 that exhibit thermolabile interactions or other variant specific interactions with their cognate partners; and

14) Variants of gp37 in which the C-terminal domain of the polypeptide is modified to include sequences that confer specific binding properties on the entire

molecule, e.g., sequences derived from avidin that recognize biotin, sequences derived from immunoglobulin heavy chain that recognize Staphylococcal A protein, sequences derived from the Fab portion of the heavy chain of monoclonal antibodies to which their respective Fab light chain counterparts could attach and form an antigen-binding site, immunoactive sequences that recognize specific antibodies, or sequences that bind specific metal ions. These ligands may be immobilized to facilitate purification and/or assembly.

10 In specific embodiments, the chimers of the invention comprise a portion consisting of at least the first 10 (N-terminal) amino acids of a first tail fiber protein fused via a peptide bond to a portion consisting of at least the last 10 (C-terminal) amino acids of a second tail fiber

15 protein. The first and second tail fiber proteins can be the same or different proteins. In another embodiment, the chimers comprise an amino acid portion in the range of the first 10-60 amino acids from a tail fiber protein fused to an amino acid portion in the range of the last 10-60 amino acids

20 from a second tail fiber protein. In another embodiment, each amino acid portion is at least 20 amino acids of the tail fiber protein. The chimers comprise portions, i.e., not full-length tail fiber proteins, fused to one another. In a preferred aspect, the first tail fiber protein portion of the

25 chimera is from gp37, and the second tail fiber protein portion is from gp36. Such a chimera (gp37-36 chimera), after oligomerization to form P37-36, can polymerize to other identical oligomers. A gp36-34 chimera, after oligomerization to form P36-34, can bind to gp35, and this unit can then

30 polymerize. In another embodiment, the first portion is from gp37, and the second portion is from gp34. In a preferred aspect, the chimers of the invention are made by insertions or deletions within a β turn of the β structure of the tail fiber proteins. Most preferably, insertions into a tail

35 fiber sequence, or fusing to another tail fiber protein sequence, (preferably via manipulation at the recombinant DNA level to produce the desired encoded protein) is done so that

sequenc s in β turns on the same edge of the β -sheet are join d.

In addition to th above-described chimers, nanostructures of the invention can also comprise tail fiber
5 protein deletion constructs that are truncated at one end, e.g., are lacking an amino- or carboxy- end (of at least 5 or 10 amino acids) of the molecule. Such molecules truncated at the amino-terminus, e.g., of truncated gp37, gp34, or gp36, can be used to "cap" a nanostructure, since, once
10 incorporated, they will terminate polymerization. Such molecules preferably comprise a fragment of a tail fiber protein lacking at least the first 10, 20, or 60 amino terminal amino acids.

In order to change the length of the rod component
15 proteins as desired, portions of the same or different tail fiber proteins can be inserted into a tail fiber chimer to lengthen the rod, or be deleted from a chimer, to shorten the rod.

20 ASSEMBLY OF INDIVIDUAL ROD COMPONENTS INTO NANOSTRUCTURES

Expression of the proteins of the present invention in *E. coli* as described above results in the synthesis of large quantities of protein, and allows the simultaneous expression and assembly of different components in the same
25 cells. The methods for scale-up of recombinant protein production are straightforward and widely known in the art, and many standard protocols can be used to recover native and modified tail fiber proteins from a bacterial culture.

In a preferred embodiment, native (nonrecombinant)
30 gp35 is isolated for use by growing up a bacteriophage T4 having an amber mutation in gene 36, in a su^0 bacterial strain (not an amber suppressor), and isolating gp35 from the resulting culture by standard methods.

P34, P36-P37, P37, and chimers derived from them
35 ar purified from *E. coli* cultures as mature dimers. Gp35 and variants ther of ar purified as monom rs. Purification is achi v d by th following procedures or combinations thereof,

using standard methods: 1) chromatography on molecular sieve, ion-exchange, and/or hydrophobic matrices; 2) preparative ultracentrifugation; and 3) affinity chromatography, using as the immobilized ligand specific antibodies or other specific binding moieties. For example, the C-terminal domain of P37 binds to the lipopolysaccharide of *E. coli* B. Other T4-like phages have P37 analogues that bind other cell surface components such as OmpF or TSX protein. Alternatively, if the proteins have been engineered to include heterologous domains that act as ligands or binding sites, the cognate partner is immobilized on a solid matrix and used in affinity purification. For example, such a heterologous domain can be biotin, which binds to a streptavidin-coated solid phase.

Alternatively, several components are co-expressed in the same bacterial cells, and sub-assemblies of larger nanostructures are purified subsequent to limited *in vivo* assembly, using the methods enumerated above.

The purified components are then combined *in vitro* under conditions where assembly of the desired nanostructure occurs at temperatures between about 4°C and about 37°C, and at pHs between about 5 and about 9. For a given nanostructure, optimal conditions for assembly (*i.e.*, type and concentration of salts and metal ions) are easily determined by routine experimentation, such as by changing each variable individually and monitoring formation of the appropriate products.

Alternatively, one or more crude bacterial extracts may be prepared, mixed, and assembly reactions allowed to proceed prior to purification.

In some cases, one or more purified components assemble spontaneously into the desired structure, without the necessity for initiators. In other cases, an initiator is required to nucleate the polymerization of rods or sheets. This offers the advantage of localizing the assembly process (*i.e.*, if the initiator is immobilized or otherwise localized) and of regulating the dimensions of the final

structur . For xample, rod components that contain a functional P36 C-terminus require a functional P37 N-terminus to initiat rod formation stoichiometrically; thus, altering the relative amount of initiator and rod component will
5 influence the average length of rod polymer. If the ratio is n, the average rod will be approximately (P37-36)n--N-terminus P37-P37 C-terminus.

In still other cases, the final nanostructure is composed of two or more components that cannot self-assemble
10 individually but only in combination with each other. In this situation, alternatng cycles of assembly can be staged to produce final products of precisely defined structure (see Example 6B below.)

When an immobilized initiator is used, it may be
15 desirable to remove the polymerized unit from the matrix after staged assembly. For this purpose specialized initiators are engineered so that the interaction with the first rod component is rendered reversibly thermolabile (see Example 5 below). In this way, the polymer can be easily
20 separated from the matrix-bound initiator, thereby permitting: 1) easy preparation of stock solutions of uniform parts or subassemblies, and 2) re-use of the matrix-bound initiator for multiple cycles of polymer initiation, growth, and release.

25 In an embodiment in which a nanostructure is assembled that is attached to a solid matrix via gp34 (or P34), one way in which to detach the nanostructure to bring it into solution is to use a mutant (thermolabile) gp34 that can be made to detach upon exposure to a higher temperature
30 (e.g., 40°C). Such a mutant gp34, termed T4 tsB45, having a mutation at its C-terminal end such that P34 attaches to the distal tail fiber half at 30°C but can be separated from it in vitro by incubation at 40°C in the presence of 1% SDS (unlike wild-type T4 which are stable under these
35 conditions), has been r ported (Seed, 1980, Studies of the Bacteriophage T4 Proximal Half Tail Fiber, Ph.D. Thesis, California Institute of Technology), and can be used.

Proteins which catalyze the formation of correct (lowest energy) stable secondary (2°) structure of proteins are called chaperone proteins. (Often, especially in globular proteins, this stabilization is aided by tertiary structure, e.g., stabilization of β -sheets by their interaction in β -barrels or by interaction with α -helices). Normally chaperonins prevent intrachain or interchain interactions which would produce untoward metastable folding intermediates and prevent or delay proper folding. There are two known accessory proteins, gp57 and gp38, in the morphogenesis of T4 phage tail fibers which are sometimes called chaperonins because they are essential for proper maturation of the protein oligomers but are not present in the final structures.

The usual chaperonin system (e.g., groEL/ES) interact with certain oligopeptide moieties of the gene product to prevent unwanted interactions with oligopeptide moieties elsewhere on the same polypeptide or another peptide. These would form metastable folding intermediates which retard or prevent proper folding of the polypeptide to its native (lower energy) state.

Gp57, probably in conjunction with some membrane protein(s), has the role of juxtaposing (and aligning) and/or initiating the folding of 2 or 3 identical gp37 molecules. The aligned peptides then zip up (while mutually stabilizing their nascent β -structures) to form a beam, without further interaction with gp57. Gp57 acts in T4 assembly not only for oligomerization of gp37 but also for gp34 and gp12.

30 STRUCTURAL COMPONENTS FOR SELF ASSEMBLY OF BEAMS IN VITRO

Alternatively to starting the polymerization of chimeras with the use of a preformed chimeric or natural oligomeric unit called an initiator produced *in vivo*, molecules (preferably peptides) that can self-assemble can be produced as fusion proteins, fused to the N- or C-terminus of tail fiber variants of the invention (chimeras, deletion/insertion constructs) to align their ends and thus

to facilitate their subsequent unaided folding into oligomeric, stable β -folded rod-like (beam) units *in vitro*, in the absence of the normally required chaperonin proteins (e.g., gp57) and host cell membrane proteins.

5 As an illustration, consider the P37 unit as an initiator of gp37-36 oligomerization and polymerization. Normally, proper folding of gp37 to a P37 initiator requires a phage infected cell membrane, and two chaperone proteins, gp38 and gp57. In a preferred embodiment, the need for gp38
10 can be obviated by use of a mutation, ts3813 (a duplication of 7 residues just downstream of the transition zone of gp37) which suppresses gene 38 (Wood, W.B., F.A. Eiserling and R.A. Crowther, 1994, "Long Tail Fibers: Genes, Proteins, Structure, and Assembly," in Molecular Biology of
15 Bacteriophage T4, (Jim D. Karam, Editor) American Society for Microbiology, Washington, D.C., pp 282-290). If a moiety that self-assembles into a dimer or trimer or other oligomer ("self-assembling moiety") is fused to a C-terminal deletion of gp37 downstream or upstream of the transition region [the
20 transition region is a conserved 17 amino acid residue region in T4-like tail fiber proteins where the structure of the protein narrows to a thin fiber; see Henning et al., 1994, "Receptor recognition by T-even-type coliphages," in Molecular Biology of Bacteriophage T4, Karam (ed.), American
25 Society for Microbiology, Washington, D.C., pp. 291-298; Wood et al., 1994, "Long tail fibers: Genes, proteins, structure, and assembly," in Molecular Biology of Bacteriophage T4, Karam (ed.), American Society for Microbiology, Washington, D.C., pp. 282-290], when it is expressed, the self-assembling
30 moiety will oligomerize in parallel and thus align the fused gp37 peptides, permitting them to fold *in vitro*, in the absence of other chaperonin proteins.

If P37 is a dimer (Figure 8A), the self-assembling moiety can be a self dimerizing peptide such as the leucine
35 zipper, made from residues 250-281 from the yeast transcription factor, GCN4 (E.K. O'Shea, R. Rutkowski and P.S. Kim, Science 243:538, 1989) or the self dimerizing mutant

1 ucine zipper peptide, pIL in which the a positions are
substitut d with isoleucine and the d positions with leucine
(Harbury P.B., T. Zhang, P.S. Kim and T. Alper. 1993. A
Switch Between Two-, Three-, and Four-Stranded Coiled Coils
5 in GCN4 Leucine Zipper Mutants. Science, 262:1401-1407). If
P37 is a trimer (Figure 8B), the self-assembling moiety can
be a self trimerizing mutant leucine zipper peptide, pII in
which both the a and d positions are substituted with
isoleucine (Harbury P.B., et al. *ibid*). Alternatively, a
10 collagen peptide can be used as the self-assembling moiety,
such as that described by Bella et al. (J. Bella, M. Eaton,
B. Brodsky and H.M. Berman. 1994. Crystal and Molecular
Structure of a Collagen-Like Peptide at 1.9Å Resolution.
Science, 226:75-81), which self aligns by an inserted
15 specific non repeating alanine residue near the center.

Self-assembling moieties can be used to make
initiators for polymerizations in the absence of the normal
initiators. For example, to create an initiator for
oligomerization and polymerization of the chimeric monomer,
20 gp37-36, gp37-36-C₂ can be used as illustrated in Figure 9.
(C₂ means that a dimer forming peptide is fused to the
C-terminus of the gp36 moiety. This is used if the beam is a
dimeric structure. Otherwise C₃ -- a trimer forming peptide
fused to the C-terminus -- would be used.) Furthermore, use
25 of the *E. coli* lac repressor N-terminus, e.g., which
associates as a tetramer, with two coils facing in each
direction could join two dimers (or polymers of dimers) end
to end, either at their N- or C-termini depending upon which
end the self-assembling peptides were placed. They could
30 also join N- to C- termini. In any case, alone, they could
only form a dimer, each end of which would be extensible by
adding an appropriate chimer monomer (as shown for the
simpler case in Figure 9).

In an alternative embodiment, the self-assembling
35 moiety can be fused to the N-termini of the chimer. In a
specific embodiment, the self-assembling moiety is fused to

at least a 10 amino acid portion of a T-even-like tail fiber prot in.

A self assembling moiety that assembles into a heteroligomer can also be used. For example, if
5 polymerization between beams is directed by the surface of a dimeric cross- β surface, addition of a heterodimeric unit with one surface which does not promote further polymerization would be very useful to cap the penultimate unit and thus terminate polymerization. If the two types of
10 coiled regions of the self-assembling moiety are much more attractive to each other than to themselves, then all of the dimers will be heterodimers. Such is the case for the N-terminal Jun and Fos leucine zipper regions.

A further advantage to such heterodimeric units is
15 the ability to stage polymerization and thus build one unit (or one surface in a 2D array) at a time. For example, suppose surface A attaches to B but neither attaches to itself ($[A \leftrightarrow B]$ is used to symbolize this type of interaction). Mix A/A and B/B₀ (B₀ is attached to a matrix
20 for easy purification). This will form B₀/B-A/A. Now wash out A/A and add B/B. The construct is now B₀/B-A/A-B/B. Now add A/A₀. The construct is now B₀/B-A/A-B/B-A/A₀ and no more beams can be added. There are of course many other possibilities.

25

APPLICATIONS

The uses of the nanostructures of the present invention are manifold and include applications that require highly regular, well-defined arrays of fibers, cages, or
30 solids, which may include specific attachment sites that allow them to associate with other materials.

In one embodiment, a three-dimensional hexagonal array of tubes is used as a molecular sieve or filter, providing regular vertical pores of precise diameter for
35 selective separation of particles by size. Such filters can be used for sterilization of solutions (i.e., to remove microorganisms or viruses), or as a series of

molecular-weight cut-off filters. In this case, the protein components of the pores may be modified so as to provide specific surface properties (i. ., hydrophilicity or hydrophobicity, ability to bind specific ligands, etc.).

5 Among the advantages of this type of filtration device is the uniformity and linearity of pores and the high pore to matrix ratio.

In another embodiment, long one-dimensional fibers are incorporated, for example, into paper or cement or
10 plastic during manufacture to provide added wet and dry tensile strength.

In still another embodiment, different nanostructure arrays are impregnated into paper and fabric as anti-counterfeiting markers. In this case, a simple
15 color-linked antibody reaction (such as those commercially available in kits) is used to verify the origin of the material. Alternatively, such nanostructure arrays could bind dyes or other substances, either before or after incorporation to color the paper or fabrics or modify their
20 appearance or properties in other ways.

KITS

The invention also provides kits for making nanostructures, comprising in one or more containers the
25 chimeras and deletion constructs of the invention. For example, one such kit comprises in one or more containers purified gp35 and purified gp36-34 chimera. Another such kit comprises purified gp37-36 chimera.

The following examples are intended to illustrate
30 the present invention without limiting its scope.

In the examples below, all restriction enzymes, nucleases, ligases, etc. are commercially available from numerous commercial sources, such as New England Biolabs (NEB), Beverly, MA; Life Technologies (GIBCO-BRL),
35 Gaithersburg, MD; and Boehringer Mannheim Corp. (BMC), Indianapolis, IN.

EXAMPLE 1**DESIGN, CONSTRUCTION AND EXPRESSION OF INTERNALLY DELETED P37**

The gene encoding gp37 contains two sites for the restriction enzyme Bgl II, the first cleavage occurring after 5 nucleotide 293 and the second after nucleotide 1486 (the nucleotides are numbered from the initiator methionine codon ATG.) Thus, digestion of a DNA fragment encoding gp37 with BglII, excision of the intervening fragment (nucleotides 294- 1485) and re-ligation of the 5' and 3' fragments results 10 in the formation of an internally deleted gp37, designated Δ P37, in which arginine-98 is joined with serine-497.

The restriction digestion reaction mix contains:

	gp37 plasmid DNA (1 μ g/ μ l)	2 μ l
15	NEB buffer #2 (10X)	1 μ l
	H ₂ O	6 μ l
	Bgl II (10 U/ μ l)	1 μ l

The gp37 plasmid signifies a pT7-5 plasmid into which gene 37 20 has been inserted in the multiple cloning site, downstream of a good ribosome binding site and of gene 57 to chaperon the dimerization. The reaction is incubated for 1h at 37°C. Then, 89 μ l of T4 DNA ligase buffer and 1 μ l of T4 DNA ligase are added, and the reaction is continued at 16°C for 4 hours. 25 2 μ l of the Stu I restriction enzyme are then added, and incubation continued at 37°C for 1h. (The Stu I restriction enzyme digests residual plasmids that were not cut by Bgl II in the first step, reducing their transformability by about 100-fold.)

30 The reaction mixture is then transformed into *E. coli* strain BL21, obtained from Novagen, using standard procedures. The transformation mixture is plated onto nutrient agar containing 100 μ g/ml ampicillin, and the plates are incubated overnight at 37°C.

35 Colonies that appear after overnight incubation are picked, and plasmid DNA is extracted and digested with Bgl II as above. The restriction digests are resolved on 1% agarose

gels. A successful deletion is evidenced by the appearance after gel electrophoresis of a new DNA fragment of 4.2 kbp, representing the undelimited part of gene 37 which is still attached to the plasmid and which re-formed a BglII site by ligation. The 1.2 kbp DNA fragment bounded by BglII sites in the original gene is no longer in the plasmid and so is missing from the gel.

Plasmids selected for the predicted deletion as above are transformed into *E. coli* strain BL21(DE3).

- 10 Transformants are grown at 30°C until the density (A_{600}) of the culture reaches 0.6. IPTG is then added to a final concentration of 0.4 mM and incubation is continued at 30°C for 2h, after which the cultures are chilled on ice. 20 μ l of the culture is then removed and added to 20 μ l of a
- 15 two-fold concentrated "cracking buffer" containing 1% sodium dodecyl sulfate, glycerol, and tracking dye. 15 μ l of this solution are loaded onto a 10% polyacrylamide gel; a second aliquot of 15 μ l is first incubated in a boiling water bath for 3 min and then loaded on the same gel. After
- 20 electrophoresis, the gel is fixed and stained. Expression of the deleted gp37 is evidenced by the appearance of a protein species migrating at an apparent molecular mass of 65-70,000 daltons in the boiled sample. The extent of dimerization is suggested by the intensity of higher-molecular mass species
- 25 in the unboiled sample and/or by the disappearance of the 65-70,000 dalton protein band.

The ability of the deleted polypeptide to dimerize appropriately is directly evaluated by testing its ability to be recognized by an anti-P37 antiserum that reacts only with mature P37 dimers, using a standard protein immunoblotting procedure.

- An alternative assay for functional dimerization of the deleted P37 polypeptide (also referred to as Δ P37) is its ability to complement *in vivo* a T4 37⁻ phage, by first
- 35 inducing expression of the Δ P37 and then infecting with the T4 mutant, and detecting progeny phage.

A Δ P37 was prepared as described above, and found capable of complementing a T4 37⁻ phag in vivo.

EXAMPLE 2

5 DESIGN, CONSTRUCTION AND EXPRESSION OF A gp37-36 CHIMER

The starting plasmid for this construction is one in which the gene encoding gp37 is cloned immediately upstream (i.e., 5') of the gene encoding gp36. The plasmid is digested with Hae III, which deletes the entire 3' region
10 of gp37 DNA downstream of nucleotide 724 to the 3' terminus, and also removes the 5' end of gp36 DNA from the 5' terminus to nucleotide 349. The reaction mixture is identical to that described in Example 1, except that a different plasmid DNA
15 is used, and the enzyme is HaeIII. Ligation using T4 DNA ligase, bacterial transformation, and restriction analysis are also performed as in Example 1. In this case, excision of the central portion of the gene 37-36 insert and religation reveals a novel insert of 346 in-frame codons, which is cut only once by HaeIII (after nucleotide 725). The
20 resulting construct is then expressed in *E. coli* BL21(DE3) as described in Example 1.

Successful expression of the gp37-36 chimera is evidenced by the appearance of a protein product of about 35,000 daltons. This protein will have the first 242
25 N-terminal amino acids of gp37 fused to the final 104 C-terminal amino acids of gp36 (numbered 118-221.) The utility of this chimera depends upon its ability to dimerize and attach end-to-end. That is, carboxy termini of said polypeptide will have the capability of interacting with the
30 amino terminus of the P37 protein dimer of bacteriophage T4 and to form an attached dimer, and the amino terminus of the dimer of said polypeptide will have the capability of interacting with other said chimera polypeptides. This property can be tested by assaying whether introduction of
35 Δ P37 initiates dimerization and polymerization. Alternatively, polyclonal antibodies specific to P36 dimer

may be used to detect P36 subsequent to initiation of dimerization by ΔP37.

A gp37-36 chimera was prepared similarly to the procedures described above, except that the restriction enzyme TaqI was used instead of HaeIII. Briefly, the 5' fragment resulting from TaqI digestion of gene 37 was ligated to the 3' fragment resulting from TaqI digestion of gene 36. This produced a construct encoding a gp37-36 chimera in which amino acids 1-48 of gp37 were fused to amino acids 100-221 of gp36. This construct was expressed in *E. coli* BL21(DE3), and the chimera was detected as an 18 kD protein. This gp37-36 chimera was found to inhibit the growth of wild type T4 when expression of the gp37-36 chimera was induced prior to infection (in an *in vitro* phage inhibition assay).

15

EXAMPLE 3

MUTATION OF THE GP37-36 CHIMER TO PRODUCE COMPLEMENTARY SUPPRESSORS

The goal of this construction is to produce two variants of a dimerizable P37-36 chimera: One in which the N-terminus of the polypeptide is mutated (A, designated *P37-36) and one in which the C-terminus of the polypeptide is mutated (B, designated P37-36*). The requirement is that the mutated *P37 N-terminus cannot form a joint with the wild-type P36 C-terminus, but only with the mutated *P36 N-terminus. The rationale is that A and B each cannot polymerize independently (as the parent P37-36 protein can), but can only associate with each other sequentially (i.e., P37-36* + *P37-36 --> P37-36*--*P37-36).

A second construct, *p37-P36*, is formed by recombining *P37-36 and P37-36* *in vitro*. When the monomers *gp37-36* and gp37-36 are mixed in the presence of P37 initiator, gp37-36 would dimerize and polymerize to (P37-36)_n; similarly, *P37 would only catalyze the polymerization of gp37-36* to (*P37-36*)_n. In this case, the two chimeras could be of different size and different primary sequence with different potential side-group

interactions, and could initiate attachment at different surfaces depending on the attachment specificity of P37. The starting bacterial strain is a su^+ strain of *E. coli* (which lacks the ability to suppress amber mutations). When this strain is infected with a mutant T4 bacteriophage containing amber mutations in genes 35, 36, and 37, phage replication is incomplete, since the tail fiber proteins cannot be synthesized. When this strain is first transformed with a plasmid that directs the expression of the wild type gp35, gp36 and gp37 genes and induced with IPTG, and subsequently infected with mutant phage, infectious phage particles are produced; this is evidenced by the appearance of "nibbled" colonies. Nibbled colonies do not appear round, with smooth edges, but rather have sectors missing. This is caused by attack of a microcolony by a single phage, which replicates and prevents the growth of the bacteria in the missing sector.

For the purposes of this construction, the 3'-terminal region of gene 36 (corresponding to the C-terminal region of gp36) is mutagenized with randomly doped oligonucleotides. Randomly doped oligonucleotides are prepared during chemical synthesis of oligonucleotides, by adding a trace amount (up to a few percent) of the other three nucleotides at a given position, so that the resulting oligonucleotide mix has a small percentage of incorrect nucleotides at that position. Incorporation of such oligonucleotides into the plasmid will result in random mutations (Hutchison et al., Methods. Enzymol. 202:356, 1991).

The mutagenized population of plasmids (containing mutations in modified genes 36 and 37), is then transformed into the su^+ bacteria, followed by infection with the mutant T4 phage as above. In this case, the appearance of non-"nibbled" colonies indicates that the mutated gp36 C-termini can no longer interact with wild type P37 to form functional tail fibers. The putative gp36* phenotypes found in such non-nibbled colonies are checked for lack of dimeric N-termini by appropriate immunospecificity as outlined above,

and positive colonies are used as source of plasmid for the next step.

Several of these mutant plasmids are recovered and subjected to a second round of mutagenesis, this time using 5 doped oligonucleotides that introduce random mutations into the N-terminal region of gp37 present on the same plasmid. Again, the (now doubly) mutagenized plasmids are transformed into the sup0 strain of *E. coli* and transformants are infected with the mutant T4 phage. At this stage, bacterial 10 plates are screened for the re-appearance of "nibbled" colonies. A nibbled colony at this stage indicates that the phage has replicated by virtue of suppression of the non-functional gp36* mutation(s) by the *P37 mutation. In other words, such colonies must contain novel *P37 15 polypeptides that have now acquired the ability to interact with the P36* proteins encoded on the same plasmid.

The *P37-36 and P37-36* paired suppressor chimeras (A and B as above) are then constructed in the same manner as described in Example 2. In this case, however, *P37 is used 20 in place of wild type P37 and P36* is used in place of wild type P36. A *P37-36* chimera can now be made by restriction of *P37-36 and P37-36* and religation in the recombined order. The *P37-36* can be mixed with the P37-36 chimera, and the polymerization of each can be accomplished independently 25 in the presence of the other. This is useful when the rod-like central portion of these chimeras have been modified in different ways.

EXAMPLE 4

30 DESIGN, CONSTRUCTION AND EXPRESSION OF A gp36-34 CHIMER

The starting plasmid for this construction is one in which the vector containing gene 57 and the gene encoding gp36 is cloned immediately upstream (i.e., 5') of the gene - encoding gp34. The plasmid is digested with NdeI, which cuts 35 after bp 219 of gene 36 and after bp 2594 of gene 34, thereby deleting the final 148 C-terminal codons from the gp36 moiety and the first 865 N-terminal codons from the gp34 moiety.

The reaction mixture is identical to that described in Example 1, except that a different plasmid DNA is used, and the enzyme used is NdeI (NEB). Ligation using T4 DNA ligase, bacterial transformation, and restriction analysis are also performed as in Example 1. This results in a new hybrid gene encoding a protein of 497 amino acids (73 N-terminal amino acids of gp36 and 424 C-terminal amino acids of gp34, numbered 866-1289.)

As an alternative, the starting plasmid is cut with SphI at bp 648 in gene 34, and the Exo-Size Deletion Kit (NEB) is used to create deletions as described above.

The resulting construct is then expressed in *E. coli* BL21(DE3) as described in Example 1. Successful expression of the gp36-34 chimera is evidenced by the appearance of a protein product of about 55,000 daltons. Preferably, the amino termini of the polypeptide homodimer have the capability of interacting with the gp35 protein, and then the carboxy termini have the capability of interacting with other attached gp35 molecules. Successful formation of the dimer can be detected by reaction with anti-P36 antibodies or by attachment of gp35 or by the *in vitro* phage inhibition assay described in Example 2.

EXAMPLE 5

ISOLATION OF THERMOLABILE PROTEINS FOR SELF-ASSEMBLY

Thermolabile structures can be utilized in nanostructures for: a) initiation of chimera polymerization (e.g., gp37-36) at low temperature and subsequent inactivation of and separation from the initiator at high temperature; b) initiation of angle formation between P36 and gp35 (e.g., variants of gp35 that have thermolabile attachment sites for P36 N-termini or P34 C-termini, a variant P36 that forms a thermolabile attachment to gp35, and a variant P34 with a thermolabile C-terminal attachment site.) Thermolability may be reversible, permitting reattachment of the appropriate termini when the lower temperature is restored, or it may be irreversible.

To create a variant gp37 that permits heat induced separation of the P36 -- P37 junction, the 5' end of gp37 DNA is randomly mutagenized using doped oligonucleotides as described above. The mutagenized DNA fragment is then
5 recombined into T4 phage by infection of the cell containing the mutagenized DNA by a T4 phage containing two amber mutations flanking the mutagenized region. Following a low-multiplicity infection, non-amber phage are selected at low temperature on *E. coli* Su^o at 30°C. The progeny of these
10 plaques are resuspended in buffered and challenged by heating at 60°C. At this temperature, wild-type tail fibers remain intact and functional, whereas the thermolabile versions release the terminal P37 units and thus render those phage non-infectious.

15 At this stage, wild type phage are removed by: 1) adsorbing the wild type phage to sensitive bacteria and sedimenting (or filtering out) the bacteria with the adsorbed wild type phage; or 2) reacting the lysate with anti-P37 antibody, followed by immobilized Protein A and removal of
20 adsorbed wild type phage. Either method leaves the noninfectious mutant phage particles in the supernatant fluid or filtrate, from which they can be recovered. The non-infectious phage lacking terminal P37 moieties (and probably the rest of the tail fibers as well) are then urea
25 treated with 6M urea, and mixed with bacterial spheroplasts to permit infection at low multiplicity whereupon they replicate at low temperature and release progeny. Alternatively, infectious phage are reconstituted by *in vitro* incubation of the mutant phage with wild type P37 at 30°C;
30 this is followed by infection of intact bacterial cells using the standard protocol. The latter method of infection specifically selects mutant phage in which the thermolability of the P36-P37 junction is reversible.

Using either method, the phage populations are
35 subjected to multiple rounds of selection as above, after which individual phage particles are isolated by plaque purification at 30°C. Finally, the putative mutants are

valuated individually for the following characteristics:

- 1) loss of infectivity after incubation at high temperatures (40-60°C), as measured by a decrease in titer; 2) loss of P37 after incubation at high temperature, as measured by decrease in binding of P37-specific antibody to phage particles; and
- 3) morphological changes in the tail fibers after incubation at high temperatures, as assessed by electron microscopy.

After mutants are isolated and their phenotypes confirmed, the P37 gene is sequenced. If the mutations localize to particular regions or residues, those sequences are targeted for site-directed mutagenesis to optimize the desired characteristics.

Finally, the mutant gene 37 is cloned into expression plasmids and expressed individually in *E. coli* as in Example 1. The mutant P37 dimers are then purified from bacterial extracts and used in *in vitro* assembly reactions.

In a similar fashion, mutant gp35 polypeptides can be isolated that exhibit a thermolabile interaction with the N-terminus of P36 or the C-terminus of P34. For thermolabile interaction with P34, phage are incubated at high temperature, resulting in the loss of the entire distal half of the tail fiber (i.e., gp35-P36-P37). The only difference in the experimental protocol is that, in this case, 1) random mutagenesis is performed over the entire gp35 gene; 2) wild-type phage (and distal half-fibers from thermolabile mutants) are separated from thermolabile mutant phage that have been inactivated at high temperature (but still have proximal half tail fibers attached) by precipitating both the distal half-fibers and the phage particles containing intact tail fibers with any of the anti-distal half tail-fiber antibodies followed by Staphylococcal A-protein beads; 3) the mutant phage remaining in the supernatant are reactivated by incubation at low temperature with bacterial extracts containing wild type intact distal half fibers; and 4) stocks of thermolabile gene, 35 mutants grown at 30°C can be tested for reversible thermolability by inactivation at 60°C and reincubation at 30°C. Inactivation is performed on a

concentrated suspension of phage, and reincubation at 30°C is performed either before or after dilution. If phage are successfully reactivated before, but not after, dilution, this indicates that their gp35 is reversibly thermolabile.

5 To create a gene 36 mutation with a thermolabile gp35--P36 linkage, the C-terminus of gene 36 is mutagenized as described above, and the mutant selected for reversibility. An alternative is to mutagenize gp35 to create a gene 35 mutant in which the gp35-P36 linkage will
10 dissociate at 60°C. In this case, incubation with anti-gp35 antibodies can be used to precipitate the phage without P36-P37 and thus to separate them from the wild-type phage and distal half-tail fibers (P36-P37), since the variant gp35 will remain attached to P34.

15

EXAMPLE 6

ASSEMBLY OF ONE-DIMENSIONAL RODS

A. Simple Assembly: The P37-36 chimera described in Example 2 is capable of self-assembly, but requires a P37
20 initiator to bind the first unit of the rod. Therefore, a P37 or a Δ P37 dimer is either attached to a solid matrix or is free in solution to serve as an initiator. If the initiator is, attached to a solid matrix, a thermolabile P37 dimer is preferably used. Addition of an extract containing
25 gp37-36, or the purified gp37-36 chimera, results in the assembly of linear multimers of increasing length. In the matrix-bound case, the final rods are released by a brief incubation at high temperature (40-60°C, depending on the characteristics of the particular thermolabile P37 variant.)

30 The ratio of initiator to gp37-36 can be varied, and the size distribution of the rods is measured by any of the following methods: 1) Size exclusion chromatography; 2) Increase in the viscosity of the solution; and 3) Direct measurement by electron microscopy.

35 B. Staged assembly: The P37-36 variants *P37-36 and P37-36* described in Example 3 cannot self-polymerize.

This allows the staged assembly of rods of defined length, according to the following protocol:

1. Attach initiator P37 (preferably thermolabile) to a matrix.
- 5 2. Add excess *gp37-36 to attach and oligomerize as P37-36 homooligomers to the N-terminus of P37.
3. Wash out unreacted *gp37-36 and flood with gp37-36*.
4. Wash out unreacted gp37-36* and flood with
10 excess *gp37-36.
5. Repeat steps 2-4, n-1 times.
6. Release assembly from matrix by brief incubation at high temperature as above.

The linear dimensions of the protein rods in the
15 batch will depend upon the lengths of the unit heterochimers and the number of cycles (n) of addition. This method has the advantage of insuring absolute reproducibility of rod length and a homogenous, monodisperse size distribution from one preparation to another.

20

EXAMPLE 7

STAGED ASSEMBLY OF POLYGONS

The following assembly strategy utilizes gp35 as an angle joint to allow the formation of polygons. For the
25 purpose of this example, the angle formed by gp35 is assumed to be 137°. The rod unit comprises the P36-34 chimera described in Example 4, which is incapable of self-polymerization. The P36-34 homodimer is made from a bacterial clone in which both gp36-34 and gp57 are expressed.
30 The gp57 can chaperone the homodimerization of gp36-34 to P36-34.

1. Initiator: The incomplete distal half fiber P36-37 is attached to a solid matrix by the P37 C-terminus. Thermolabile gp35 as described in Example 5 is then added to
35 form the intact initiator.

2. Excess P36-34 chimera is added to attach a single P36-34. Following binding to the matrix via gp35, the unbound chimera is washed out.

3. Wild-type (i.e., non-thermolabile) gp35 is then added in excess. After incubation, the unbound material is washed out.

4. Steps 2 and 3 are repeated 7-8 times.

5. The assembly is released from the matrix by brief incubation at high temperature.

10 The released polymeric rod, 8 units long, will form a regular 8-sided polygon, whose sides comprise the P36-34 dimer and whose joints comprise the wild-type gp35 monomer. However, there will be some multimers of these 8 units bound as helices. When a unit does not close, but
15 instead adds another to its terminus, the unit cannot close further and the helix can build in either direction. The direction of the first overlap also determines the handedness of the helix. Ten (or seven)-unit rods may form helices more frequently than polygons since their natural angles are 144°
20 (or 128.6°). The likelihood of closure of a regular polygon depends not only on the average angle of gp35 but also on its flexibility, which can be further manipulated by genetic or environmental modification.

The type of polygon that is formed using this
25 protocol depends upon the length of rod units and the angle formed by the angle joint. For example, alternating rod units of different sizes can be used in step 2. In addition, variant gp35 polypeptides that form angles different than the natural angle of 137° can be used, allowing the formation of
30 different regular polygons. Furthermore, for a given polygon with an even number of sides and equal angles, the sides in either half can be of any size provided the two halves are symmetric.

35

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Goldberg, Edward B.
- (ii) TITLE OF INVENTION: MATERIALS FOR THE PRODUCTION OF NANOMETER STRUCTURES AND USE THEREOF
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Pennie and Edmonds
 - (B) STREET: 1155 Avenue of the Americas
 - (C) CITY: New York
 - (D) STATE: New York
 - (E) COUNTRY: US
 - (F) ZIP: 10036
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To be Assigned
 - (B) FILING DATE: 13-OCT-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Misrock, S. Leslie
 - (B) REGISTRATION NUMBER: 18,872
 - (C) REFERENCE/DOCKET NUMBER: 8471-0005-999
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (212) 790-9090
 - (B) TELEFAX: 212-869-8864
 - (C) TELEX: 66441 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8855 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacteriophage T4
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: TAIL FIBER GENES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TAGGAGCCCG GGAGAATGGC CGAGATTAA AGAGAATTCA GAGCAGAAGA TGGTCTGGAC

60

GCAGGTGGTG	ATAAAATAAT	CAACGTAGCT	TTAGCTGATC	GTACCGTAGG	AACTGACGGT	120
GTTAACGTTG	ATTACTTAAT	TCAAGAAAAC	ACAGTTCAAC	AGTATGATCC	AACTCGTGGA	180
TATTTAAAAG	ATTTTGTAAAT	CATTTATGAT	AACCGCTTTT	GGGCTGCTAT	AAATGATATT	240
CCAAAACCG	CAGGAGCTTT	TAATAGCGGA	CGCTGGAGAG	CATTACGTAC	CGATGCTAAC	300
TGGATTACGG	TTTCATCTGG	TTCATATCAA	TTAAAATCTG	GTGAAGCAAT	TTCGGTTAAC	360
ACCGCAGCTG	GAAATGACAT	CACGTTTACT	TTACCATCTT	CTCCAATTGA	TGGTGATACT	420
ATCGTTCTCC	AAGATATTGG	AGGAAAACCT	GGAGTTAACC	AAGTTTTAAT	TGTAGCTCCA	480
GTACAAAGTA	TTGTAAACTT	TAGAGGTGAA	CAGGTACGTT	CAGTACTAAT	GACTCATCCA	540
AAGTCACAGC	TAGTTTTAAT	TTTTAGTAAT	CGTCTGTGGC	AAATGTATGT	TGCTGATTAT	600
AGTAGAGAAG	CTATAGTTGT	AACACCAGCG	AATACTTATC	AAGCGCAATC	CAACGATTTT	660
ATCGTACGTA	GATTTACTTC	TGCTGCACCA	ATTAATGTCA	AACTTCCAAG	ATTTGCTAAT	720
CATGGCGATA	TTATTAATTT	CGTCGATTTA	GATAAACTAA	ATCCGCTTTA	TCATACAATT	780
GTTACTACAT	ACGATGAAAC	GACTTCAGTA	CAAGAAGTTG	GAATCATTTC	CATTGAAGGC	840
CGTACATCGA	TTGACGGTTT	CTTGATGTTT	GATGATAATG	AGAAATTATG	GAGACTGTTT	900
GACGGGGATA	GTAAAGCGCG	TTTACGTATC	ATAACGACTA	ATTCAAACAT	TCGTCCAAAT	960
GAAGAAGTTA	TGGTATTTGG	TGCGAATAAC	GGAACAACCTC	AAACAATTGA	GCTTAAGCTT	1020
CCAACATAATA	TTTCTGTTGG	TGATACTGTT	AAAATTTCCA	TGAATTACAT	GAGAAAAGGA	1080
CAAACAGTTA	AAATCAAAGC	TGCTGATGAA	GATAAAATTG	CTTCTTCAGT	TCAATTGCTG	1140
CAATTCCCAA	AACGCTCAGA	ATATCCACCT	GAAGCTGAAT	GGGTTACAGT	TCAAGAATTA	1200
GTTTTTAACG	ATGAAACTAA	TTATGTTCCA	GTTTTGGAGC	TTGCTTACAT	AGAAGATTCT	1260
GATGGAAAAT	ATTGGGTTGT	ACAGCAAAAC	GTTCCAACCTG	TAGAAAGAGT	AGATTCTTTA	1320
AATGATTCTA	CTAGAGCAAG	ATTAGGCGTA	ATTGCTTTAG	CTACACAAGC	TCAAGCTAAT	1380
GTCGATTTAG	AAAATTCTCC	ACAAAAAGAA	TTAGCAATTA	CTCCAGAAAC	GTTAGCTAAT	1440
CGTACTGCTA	CAGAAACTCG	CAGAGGTATT	GCAAGAATAG	CAACTACTGC	TCAAGTGAAT	1500
CAGAACACCA	CATTCTCTTT	TGCTGATGAT	ATTATCATCA	CTCCTAAAAA	GCTGAATGAA	1560
AGAACTGCTA	CAGAAACTCG	TAGAGGTGTC	GCAGAAATTG	CTACGCAGCA	AGAAACTAAT	1620
GCAGGAACCG	ATGATACTAC	AATCATCACT	CCTAAAAAGC	TTCAAGCTCG	TCAAGGTTCT	1680
GAATCATTAT	CTGGTATTGT	AACCTTTGTA	TCTACTGCAG	GTGCTACTCC	AGCTTCTAGC	1740
CGTGAATTAA	ATGGTACGAA	TGTTTATAAT	AAAAACACTG	ATAATTTAGT	TGTTTCACCT	1800
AAAGCTTTGG	ATCAGTATAA	AGCTACTCCA	ACACAGCAAG	GTGCAGTAAT	TTTAGCAGTT	1860
GAAAGTGAAG	TAATTGCTGG	ACAAAGTCAG	CAAGGATGGG	CAAATGCTGT	TGTAACGCCA	1920
GAAACGTTAC	ATAAAAAGAC	ATCAACTGAT	GGAAGAATTG	GTTTAATTGA	AATTGCTACG	1980
CAAAGTGAAG	TTAATACAGG	AACTGATTAT	ACTCGTGCAG	TCACTCCTAA	AACTTTAAAT	2040
GACCGTAGAG	CAACTGAAAG	TTTAAGTGGT	ATAGCTGAAA	TTGCTACACA	AGTTGAATTC	2100

GACGCAGGCG TCGACGATAC TCGTATCTCT ACACCATTAA AAATTAAAAC CAGATTTAAT 2160
AGTACTGATC GTACTTCTGT TGTGCTCTA TCTGGATTAG TTGAATCAGG AACTCTCTGG 2220
GACCATTATA CACTTAATAT TCTTGAAGCA AATGAGACAC AACGTGGTAC ACTTCGTGTA 2280
GCTACGCAGG TCGAAGCTGC TGCGGGAACA TTAGATAATG TTTTAATAAC TCCTAAAAAG 2340
CTTTTAGGTA CTAAATCTAC TGAAGCGCAA GAGGGTGTTA TTAAAGTTGC AACTCAGTCT 2400
GAAACTGTGA CTGGAACGTC AGCAAATACT GCTGTATCTC CAAAAAATTT AAAATGGATT 2460
GCGCAGAGTG AACCTACTTG GGCAGCTACT ACTGCAATAA GAGGTTTTGT TAAAACTTCA 2520
TCTGGTTCAA TTACATTCGT TGGTAATGAT ACAGTCGGTT CTACCCAAGA TTTAGAACTG 2580
TATGAGAAAA ATAGCTATGC GGTATCACCA TATGAATTAA ACCGTGTATT AGCAAATTAT 2640
TTGCCACTAA AAGCAAAAGC TGCTGATACA AATTTATTGG ATGGTCTAGA TTCATCTCAG 2700
TTCATTCGTA GGGATATTGC ACAGACGGTT AATGGTTCAC TAACCTTAAC CCAACAAACG 2760
AATCTGAGTG CCCCTCTTGT ATCATCTAGT ACTGGTGAAT TTGGTGGTTC ATTGGCCGCT 2820
AATAGAACAT TTACCATCCG TAATACAGGA GCCCCGACTA GTATCGTTTT CGAAAAAGGT 2880
CCTGCATCCG GGGCAAATCC TGCACAGTCA ATGAGTATTC GTGTATGGGG TAACCAATTT 2940
GGCGGCGGTA GTGATACGAC CCGTTCGACA GTGTTTGAAG TTGGCGATGA CACATCTCAT 3000
CACTTTTATT CTCAACGTAA TAAAGACGGT AATATAGCGT TTAACATTAA TGGTACTGTA 3060
ATGCCAATAA ACATTAATGC TTCCGGTTTG ATGAATGTGA ATGGCACTGC AACATTCGGT 3120
CGTTCAGTTA CAGCCAATGG TGAATTCATC AGCAAGTCTG CAAATGCTTT TAGAGCAATA 3180
AACGGTGATT ACGGATTCTT TATTCGTAAT GATGCCTCTA ATACCTATTT TTTGCTCACT 3240
GCAGCCGGTG ATCAGACTGG TGGTTTTAAT GGATTACGCC CATTATTAAT TAATAATCAA 3300
TCCGGTCAGA TTACAATTGG TGAAGGCTTA ATCATTGCCA AAGGTGTTAC TATAAATTCA 3360
GGCGGTTTAA CTGTAACTC GAGAATTCGT TCTCAGGGTA CTAAAACATC TGATTTATAT 3420
ACCCGTGCGC CAACATCTGA TACTGTAGGA TTCTGGTCAA TCGATATTAA TGATTCAGCC 3480
ACTTATAACC AGTTCCCGGG TTATTTTAAA ATGGTTGAAA AAACATAATGA AGTGACTGGG 3540
CTTCCATACT TAGAACGTGG CGAAGAAGTT AAATCTCCTG GTACACTGAC TCAGTTTGGT 3600
AACACACTTG ATTCGCTTTA CCAAGATTGG ATTACTTATC CAACGACGCC AGAAGCGCGT 3660
ACCACTCGCT GGACACGTAC ATGGCAGAAA ACCAAAAACT CTTGGTCAAG TTTTGTTTCA 3720
GTATTTGACG GAGGTAACCC TCCTCAACCA TCTGATATCG GTGCTTTACC ATCTGATAAT 3780
GCTACAATGG GGAATCTTAC TATTCGTGAT TTCTTGCGAA TTGGTAATGT TCGCATTGTT 3840
CCTGACCCAG TGAATAAAAC GGTAAATTT GAATGGGTTG AATAAGAGGT ATTATGGAAA 3900
AATTTATGGC CGAGATTTGG ACAAGGATAT GTCCAAACGC CATTTTATCG GAAAGTAATT 3960
CAGTAAGATA TAAAATAAGT ATAGCGGGTT CTTGCCCCGCT TTCTACAGCA GGACCATCAT 4020
ATGTTAAATT TCAGGATAAT CCTGTAGGAA GTCAAACATT TAGGCGCAGG CCTTCATTTA 4080
AGAGTTTTTG ACCCTTCCAC CGGAGCATTG GTTGATAGTA AGTCATATGC TTTTTCGACT 4140

TCAAATGATA	CTACATCAGC	TGCTTTTGTT	AGTTTTTCATG	AATTCCTTGA	CGAATAATCG	4200
AATTGTTGCT	ATATTAACTA	GTGGAAAGGT	TAATTTTCCT	CCTGAAGTAG	TATCTTG GTT	4260
AAGAACCGCC	GGAACGTCTG	CCTTTCCATC	TGATTCTATA	TTGTCAAGAT	TTGACGTATC	4320
ATATGCTGCT	TTTTATACTT	CTTCTAAAAG	AGCTATCGCA	TTAGAGCATG	TTAAACTGAG	4380
TAATAGAAAA	AGCACAGATG	ATTATCAAAC	TATTTTAGAT	GTTGTATTTG	ACAGTTTAGA	4440
AGATGTAGGA	GCTACCGGGT	TTCCAAGAAG	AACGTATGAA	AGTGTGAGC	AATTCATGTC	4500
GGCAGTTGGT	GGAACATAA	ACGAAATTGC	GAGATTGCCA	ACTTCAGCTG	CTATAAGTAA	4560
ATTATCTGAT	TATAATTTAA	TTCCTGGAGA	TGTTCTTTAT	CTTAAAGCTC	AGTTATATGC	4620
TGATGCTGAT	TTACTTGCTC	TTGGAACAC	AAATATATCT	ATCCGTTTTT	ATAATGCATC	4680
TAACGGATAT	ATTTCTTCAA	CACAAGCTGA	ATTTACTGGG	CAAGCTGGGT	CATGGGAATT	4740
AAAGGAAGAT	TATGTAGTTG	TTCCAGAAAA	CGCAGTAGGA	TTTACGATAT	ACGCACAGAG	4800
AACTGCACAA	GCTGGCCAAG	GTGGCATGAG	AAATTTAAGC	TTTTCTGAAG	TATCAAGAAA	4860
TGGCGGCATT	TCGAAACCTG	CTGAATTTGG	CGTCAATGGT	ATTCGTGTTA	ATTATATCTG	4920
CGAATCCGCT	TCACCTCCGG	ATATAATGGT	ACTTCCTACG	CAAGCATCGT	CTAAAACCTGG	4980
TAAAGTGTTT	GGGCAAGAAT	TTAGAGAAGT	TTAAATTGAG	GGACCCCTTCG	GGTTCCCTTT	5040
TTCTTTATAA	ATACTATTCA	AATAAAGGGG	CATACAATGG	CTGATTTAAA	AGTAGGTTCA	5100
ACAACCTGGAG	GCTCTGTCAT	TTGGCATCAA	GGAATTTTTC	CATTGAATCC	AGCCGGTGAC	5160
GATGTACTCT	ATAAATCATT	TAAAATATAT	TCAGAATATA	ACAAACCACA	AGCTGCTGAT	5220
AACGATTTTCG	TTTCTAAAGC	TAATGGTGGT	ACTTATGCAT	CAAAGGTAAC	ATTTAACGCT	5280
GGCATTCAAG	TCCCATATGC	TCCAAACATC	ATGAGCCCAT	GCGGGATTTA	TGGGGGTAAC	5340
GGTGATGGTG	CTACTTTTGA	TAAAGCAAAT	ATCGATATTG	TTTCATGGTA	TGGCGTAGGA	5400
TTTAAATCGT	CATTTGGTTC	AACAGGCCGA	ACTGTTGTAA	TTAATACACG	CAATGGTGAT	5460
ATTAACACAA	AAGGTGTTGT	GTCGGCAGCT	GGTCAAGTAA	GAAGTGGTGC	GGCTGCTCCT	5520
ATAGCAGCGA	ATGACCTTAC	TAGAAAGGAC	TATGTTGATG	GAGCAATAAA	TACTGTTACT	5580
GCAAATGCAA	ACTCTAGGGT	GCTACGGTCT	GGTGACACCA	TGACAGGTAA	TTTAACAGCG	5640
CCAAACTTTT	TCTCGCAGAA	TCCTGCATCT	CAACCCTCAC	ACGTTCCACG	ATTTGACCAA	5700
ATCGTAATTA	AGGATTCTGT	TCAAGATTTC	GGCTATTATT	AAGAGGACTT	ATGGCTACTT	5760
TAAAACAAAT	ACAATTTAAA	AGAAGCAAAA	TCGCAGGAAC	ACGTCCTGCT	GCTTCAGTAT	5820
TAGCCGAAGG	TGAATTGGCT	ATAAACTTAA	AAGATAGAAC	AATTTTACT	AAAGATGATT	5880
CAGGAAATAT	CATCGATCTA	GGTTTTGCTA	AAGGCGGGCA	AGTTGATGGC	AACGTTACTA	5940
TTAACGGACT	TTTGAGATTA	AATGGCGATT	ATGTACAAAC	AGGTGGAATG	ACTGTAAACG	6000
GACCCATTGG	TTCTACTGAT	GGCGTCACTG	GAAAAATTTT	CAGATCTACA	CAGGGTTCAT	6060
TTTATGCAAG	AGCAACAAAC	GATACTTCAA	ATGCCCATTT	ATGGTTTGAA	AATGCCGATG	6120
GCACTGAACG	TGGCGTTATA	TATGCTCGCC	CTCAAACCTAC	AACTGACGGT	GAAATACGCC	6180

TTAGGGTTAG	ACAAGGAACA	GGAAGCACTG	CCAACAGTGA	ATTCTATTTT	CGCTCTATAA	6240
ATGGAGGCGA	ATTTCAAGGCT	AACCGTATTT	TAGCATCAGA	TTCGTTAGTA	ACAAAACGCA	6300
TTGCGGTTGA	TACCGTTATT	CATGATGCCA	AAGCATTGTT	ACAATATGAT	TCTCACTCTT	6360
TGGTTAATTA	TGTTTATCCT	GGAACCGGTG	AAACAAATGG	TGTAAACTAT	CTTCGTAAAG	6420
TTCGCGCTAA	GTCCGGTGGT	ACAATTTATC	ATGAAATTGT	TACTGCACAA	ACAGGCCTGG	6480
CTGATGAAGT	TTCTTGGTGG	TCTGGTGATA	CACCAGTATT	TAAACTATAC	GGTATTCGTG	6540
ACGATGGCAG	AATGATTATC	CGTAATAGCC	TTGCATTAGG	TACATTCACT	ACAAATTTCC	6600
CGTCTAGTGA	TTATGGCAAC	GTCGGTGTA	TGGGCGATAA	GTATCTTGTT	CTCGGCGACA	6660
CTGTAACTGG	CTTGTCATAC	AAAAAACTG	GTGTATTTGA	TCTAGTTGGC	GGTGGATATT	6720
CTGTTGCTTC	TATTACTCCT	GACAGTTTCC	GTAGTACTCG	TAAAGGTATA	TTTGGTCGTT	6780
CTGAGGACCA	AGGCGCAACT	TGGATAATGC	CTGGTACAAA	TGCTGCTCTC	TTGTCTGTTC	6840
AAACACAAGC	TGATAATAAC	AATGCTGGAG	ACGGACAAAC	CCATATCGGG	TACAATGCTG	6900
GCGGTAAAAT	GAACCACTAT	TTCCGTGGTA	CAGGTCAGAT	GAATATCAAT	ACCCAACAAG	6960
GTATGGAAAT	TAACCCGGGT	ATTTTGAAAT	TGGTAACTGG	CTCTAATAAT	GTACAATTTT	7020
ACGCTGACGG	AACTATTTCT	TCCATTCAAC	CTATTAAATT	AGATAACGAG	ATATTTTTTA	7080
CTAAATCTAA	TAATACTGCG	GGTCTTAAAT	TTGGAGCTCC	TAGCCAAGTT	GATGGCACAA	7140
GGACTATCCA	ATGGAACGGT	GGTACTCGCG	AAGGACAGAA	TAAAACTAT	GTGATTATTA	7200
AAGCATGGGG	TAACTCATTT	AATGCCACTG	GTGATAGATC	TCGCGAAACG	GTTTTCCAAG	7260
TATCAGATAG	TCAAGGATAT	TATTTTTATG	CTCATCGTAA	AGCTCCAACC	GGCGACGAAA	7320
CTATTGGACG	TATTGAAGCT	CAATTTGCTG	GGGATGTTTA	TGCTAAAGGT	ATTATTGCCA	7380
ACGGAAATTT	TAGAGTTGTT	GGGTCAAGCG	CTTTAGCCGG	CAATGTTACT	ATGTCTAACG	7440
GTTTGTTTGT	CCAAGGTGGT	TCTTCTATTA	CTGGACAAGT	TAAAATTGGC	GGAACAGCAA	7500
ACGCACTGAG	AATTTGGAAC	GCTGAATATG	GTGCTATTTT	CCGTCGTTTC	GAAAGTAACT	7560
TTTATATTAT	TCCAACCAAT	CAAAATGAAG	GAGAAAGTGG	AGACATTCAC	AGCTCTTTGA	7620
GACCTGTGAG	AATAGGATTA	AACGATGGCA	TGGTTGGGTT	AGGAAGAGAT	TCTTTTATAG	7680
TAGATCAAAA	TAATGCTTTA	ACTACGATAA	ACAGTAACTC	TCGCATTAAT	GCCAACTTTA	7740
GAATGCAATT	GGGGCAGTCG	GCATACATTG	ATGCAGAATG	TACTGATGCT	GTTCCGCCGG	7800
CGGGTGCAGG	TTCAATTTGCT	TCCCAGAATA	ATGAAGACGT	CCGTGCGCCG	TTCTATATGA	7860
ATATTGATAG	AACTGATGCT	AGTGCATATG	TTCTATTTT	GAAACAACGT	TATGTTCAAG	7920
GCAATGGCTG	CTATTCATTA	GGGACTTTAA	TTAATAATGG	TAATTTCCGA	GTTTCATTACC	7980
ATGGCGGCGG	AGATAACGGT	TCTACAGGTC	CACAGACTGC	TGATTTTGGA	TGGGAATTTA	8040
TTAAAAACGG	TGATTTTATT	TCACCTCGCG	ATTTAATAGC	AGGCAAAGTC	AGATTTGATA	8100
GAACTGGTAA	TATCACTGGT	GGTTCTGGTA	ATTTTGCTAA	CTTAAACAGT	ACAATTGAAT	8160
CACTTAAAC	TGATATCATG	TCGAGTTACC	CAATTGGTGC	TCCGATTCCT	TGGCCGAGTG	8220

```

ATTCAGTTCC TGCTGGATTT GCTTTGATGG AAGGTCAGAC CTTTGATAAG TCCGCATATC      8280
CAAAGTTAGC TGTTGCATAT CCTAGCGGTG TTATTCCAGA TATGCGCGGG CAAACTATCA      8340
AGGGTAAACC AAGTGGTCGT GCTGTTTTGA GCGCTGAGGC AGATGGTGTT AAGGCTCATA      8400
GCCATAGTGC ATCGGCTTCA AGTACTGACT TAGGTACTAA AACCACATCA AGCTTTGACT      8460
ATGGTACGAA GGGAACTAAC AGTACGGGTG GACACACTCA CTCTGGTAGT GGTCTACTA      8520
GCACAAATGG TGAGCACAGC CACTACATCG AGGCATGGAA TGGTACTGGT GTAGGTGGTA      8580
ATAAGATGTC ATCATATGCC ATATCATACA GGGCGGGTGG GAGTAACACT AATGCAGCAG      8640
GGAACCACAG TCACACTTTC TCTTTTGGGA CTAGCAGTGC TGGCGACCAT TCCCACTCTG      8700
TAGGTATTGG TGCTCATACC CACACGGTAG CAATTGGATC ACATGGTCAT ACTATCACTG      8760
TAAATAGTAC AGGTAATACA GAAAACACGG TTAAAAACAT TGCTTTTAAC TATATCGTTC      8820
GTTTAGCATA AGGAGAGGGG CTTCGGCCCT TCTAA                                  8855

```

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1289 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacteriophage T4
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: p34 amino acid
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Glu	Ile	Lys	Arg	Glu	Phe	Arg	Ala	Glu	Asp	Gly	Leu	Asp	Ala	1	5	10	15
Gly	Gly	Asp	Lys	Ile	Ile	Asn	Val	Ala	Leu	Ala	Asp	Arg	Thr	Val	Gly	20	25	30	
Thr	Asp	Gly	Val	Asn	Val	Asp	Tyr	Leu	Ile	Gln	Glu	Asn	Thr	Val	Gln	35	40	45	
Gln	Tyr	Asp	Pro	Thr	Arg	Gly	Tyr	Leu	Lys	Asp	Phe	Val	Ile	Ile	Tyr	50	55	60	
Asp	Asn	Arg	Phe	Trp	Ala	Ala	Ile	Asn	Asp	Ile	Pro	Lys	Pro	Ala	Gly	65	70	75	80
Ala	Phe	Asn	Ser	Gly	Arg	Trp	Arg	Ala	Leu	Arg	Thr	Asp	Ala	Asn	Trp	85	90	95	
Ile	Thr	Val	Ser	Ser	Gly	Ser	Tyr	Gln	Leu	Lys	Ser	Gly	Glu	Ala	Ile	100	105	110	
Ser	Val	Asn	Thr	Ala	Ala	Gly	Asn	Asp	Ile	Thr	Phe	Thr	Leu	Pro	Ser	115	120	125	
Ser	Pro	Ile	Asp	Gly	Asp	Thr	Ile	Val	Leu	Gln	Asp	Ile	Gly	Gly	Lys	130	135	140	

Pro Gly Val Asn Gln Val L u Ile Val Ala Pro Val Gln Ser Ile Val
 145 150 155 160
 Asn Ph Arg Gly Glu Gln Val Arg Ser Val Leu Met Thr His Pro Lys
 165 170 175
 Ser Gln Leu Val Leu Ile Phe Ser Asn Arg Leu Trp Gln Met Tyr Val
 180 185 190
 Ala Asp Tyr Ser Arg Glu Ala Ile Val Val Thr Pro Ala Asn Thr Tyr
 195 200 205
 Gln Ala Gln Ser Asn Asp Phe Ile Val Arg Arg Phe Thr Ser Ala Ala
 210 215 220
 Pro Ile Asn Val Lys Leu Pro Arg Phe Ala Asn His Gly Asp Ile Ile
 225 230 235 240
 Asn Phe Val Asp Leu Asp Lys Leu Asn Pro Leu Tyr His Thr Ile Val
 245 250 255
 Thr Thr Tyr Asp Glu Thr Thr Ser Val Gln Glu Val Gly Thr His Ser
 260 265 270
 Ile Glu Gly Arg Thr Ser Ile Asp Gly Phe Leu Met Phe Asp Asp Asn
 275 280 285
 Glu Lys Leu Trp Arg Leu Phe Asp Gly Asp Ser Lys Ala Arg Leu Arg
 290 295 300
 Ile Ile Thr Thr Asn Ser Asn Ile Arg Pro Asn Glu Glu Val Met Val
 305 310 315 320
 Phe Gly Ala Asn Asn Gly Thr Thr Gln Thr Ile Glu Leu Lys Leu Pro
 325 330 335
 Thr Asn Ile Ser Val Gly Asp Thr Val Lys Ile Ser Met Asn Tyr Met
 340 345 350
 Arg Lys Gly Gln Thr Val Lys Ile Lys Ala Ala Asp Glu Asp Lys Ile
 355 360 365
 Ala Ser Ser Val Gln Leu Leu Gln Phe Pro Lys Arg Ser Glu Tyr Pro
 370 375 380
 Pro Glu Ala Glu Trp Val Thr Val Gln Glu Leu Val Phe Asn Asp Glu
 385 390 395 400
 Thr Asn Tyr Val Pro Val Leu Glu Leu Ala Tyr Ile Glu Asp Ser Asp
 405 410 415
 Gly Lys Tyr Trp Val Val Gln Gln Asn Val Pro Thr Val Glu Arg Val
 420 425 430
 Asp Ser Leu Asn Asp Ser Thr Arg Ala Arg Leu Gly Val Ile Ala Leu
 435 440 445
 Ala Thr Gln Ala Gln Ala Asn Val Asp Leu Glu Asn Ser Pro Gln Lys
 450 455 460
 Glu Leu Ala Ile Thr Pro Glu Thr Leu Ala Asn Arg Thr Ala Thr Glu
 465 470 475 480
 Thr Arg Arg Gly Ile Ala Arg Ile Ala Thr Thr Ala Gln Val Asn Gln
 485 490 495
 Asn Thr Thr Phe Ser Phe Ala Asp Asp Ile Ile Il Thr Pro Lys Lys

500					505					510					
Leu	Asn	Glu	Arg	Thr	Ala	Thr	Glu	Thr	Arg	Arg	Gly	Val	Ala	Glu	Ile
		515					520					525			
Ala	Thr	Gln	Gln	Glu	Thr	Asn	Ala	Gly	Thr	Asp	Asp	Thr	Thr	Ile	Il
		530					535					540			
Thr	Pro	Lys	Lys	Leu	Gln	Ala	Arg	Gln	Gly	Ser	Glu	Ser	Leu	Ser	Gly
															560
Ile	Val	Thr	Phe	Val	Ser	Thr	Ala	Gly	Ala	Thr	Pro	Ala	Ser	Ser	Arg
				565					570						575
Glu	Leu	Asn	Gly	Thr	Asn	Val	Tyr	Asn	Lys	Asn	Thr	Asp	Asn	Leu	Val
			580						585						590
Val	Ser	Pro	Lys	Ala	Leu	Asp	Gln	Tyr	Lys	Ala	Thr	Pro	Thr	Gln	Gln
			595				600					605			
Gly	Ala	Val	Ile	Leu	Ala	Val	Glu	Ser	Glu	Val	Ile	Ala	Gly	Gln	Ser
							615					620			
Gln	Gln	Gly	Trp	Ala	Asn	Ala	Val	Val	Thr	Pro	Glu	Thr	Leu	His	Lys
							630					635			640
Lys	Thr	Ser	Thr	Asp	Gly	Arg	Ile	Gly	Leu	Ile	Glu	Ile	Ala	Thr	Gln
				645					650						655
Ser	Glu	Val	Asn	Thr	Gly	Thr	Asp	Tyr	Thr	Arg	Ala	Val	Thr	Pro	Lys
				660					665						670
Thr	Leu	Asn	Asp	Arg	Arg	Ala	Thr	Glu	Ser	Leu	Ser	Gly	Ile	Ala	Glu
				675					680						685
Ile	Ala	Thr	Gln	Val	Glu	Phe	Asp	Ala	Gly	Val	Asp	Asp	Thr	Arg	Ile
				690					695						700
Ser	Thr	Pro	Leu	Lys	Ile	Lys	Thr	Arg	Phe	Asn	Ser	Thr	Asp	Arg	Thr
															720
Ser	Val	Val	Ala	Leu	Ser	Gly	Leu	Val	Glu	Ser	Gly	Thr	Leu	Trp	Asp
				725					730						735
His	Tyr	Thr	Leu	Asn	Ile	Leu	Glu	Ala	Asn	Glu	Thr	Gln	Arg	Gly	Thr
				740					745						750
Leu	Arg	Val	Ala	Thr	Gln	Val	Glu	Ala	Ala	Ala	Gly	Thr	Leu	Asp	Asn
				755					760						765
Val	Leu	Ile	Thr	Pro	Lys	Lys	Leu	Leu	Gly	Thr	Lys	Ser	Thr	Glu	Ala
															780
Gln	Glu	Gly	Val	Ile	Lys	Val	Ala	Thr	Gln	Ser	Glu	Thr	Val	Thr	Gly
															800
Thr	Ser	Ala	Asn	Thr	Ala	Val	Ser	Pro	Lys	Asn	Leu	Lys	Trp	Ile	Ala
				805					810						815
Gln	Ser	Glu	Pro	Thr	Trp	Ala	Ala	Thr	Thr	Ala	Ile	Arg	Gly	Phe	Val
				820					825						830
Lys	Thr	Ser	Ser	Gly	Ser	Ile	Thr	Phe	Val	Gly	Asn	Asp	Thr	Val	Gly
				835					840						845
Ser	Thr	Gln	Asp	Leu	Glu	Leu	Tyr	Glu	Lys	Asn	Ser	Tyr	Ala	Val	Ser
				850											860

Pro Tyr Glu Leu Asn Arg Val Leu Ala Asn Tyr Leu Pro Leu Lys Ala
 865 870 875 880
 Lys Ala Ala Asp Thr Asn L u Leu Asp Gly Leu Asp Ser Ser Gln Phe
 885 890 895
 Ile Arg Arg Asp Ile Ala Gln Thr Val Asn Gly Ser Leu Thr Leu Thr
 900 905 910
 Gln Gln Thr Asn Leu Ser Ala Pro Leu Val Ser Ser Ser Thr Gly Glu
 915 920 925
 Phe Gly Gly Ser Leu Ala Ala Asn Arg Thr Phe Thr Ile Arg Asn Thr
 930 935 940
 Gly Ala Pro Thr Ser Ile Val Phe Glu Lys Gly Pro Ala Ser Gly Ala
 945 950 955 960
 Asn Pro Ala Gln Ser Met Ser Ile Arg Val Trp Gly Asn Gln Phe Gly
 965 970 975
 Gly Gly Ser Asp Thr Thr Arg Ser Thr Val Phe Glu Val Gly Asp Asp
 980 985 990
 Thr Ser His His Phe Tyr Ser Gln Arg Asn Lys Asp Gly Asn Ile Ala
 995 1000 1005
 Phe Asn Ile Asn Gly Thr Val Met Pro Ile Asn Ile Asn Ala Ser Gly
 1010 1015 1020
 Leu Met Asn Val Asn Gly Thr Ala Thr Phe Gly Arg Ser Val Thr Ala
 1025 1030 1035 1040
 Asn Gly Glu Phe Ile Ser Lys Ser Ala Asn Ala Phe Arg Ala Ile Asn
 1045 1050 1055
 Gly Asp Tyr Gly Phe Phe Ile Arg Asn Asp Ala Ser Asn Thr Tyr Phe
 1060 1065 1070
 Leu Leu Thr Ala Ala Gly Asp Gln Thr Gly Gly Phe Asn Gly Leu Arg
 1075 1080 1085
 Pro Leu Leu Ile Asn Asn Gln Ser Gly Gln Ile Thr Ile Gly Glu Gly
 1090 1095 1100
 Leu Ile Ile Ala Lys Gly Val Thr Ile Asn Ser Gly Gly Leu Thr Val
 1105 1110 1115 1120
 Asn Ser Arg Ile Arg Ser Gln Gly Thr Lys Thr Ser Asp Leu Tyr Thr
 1125 1130 1135
 Arg Ala Pro Thr Ser Asp Thr Val Gly Phe Trp Ser Ile Asp Ile Asn
 1140 1145 1150
 Asp Ser Ala Thr Tyr Asn Gln Phe Pro Gly Tyr Phe Lys Met Val Glu
 1155 1160 1165
 Lys Thr Asn Glu Val Thr Gly Leu Pro Tyr Leu Glu Arg Gly Glu Glu
 1170 1175 1180
 Val Lys Ser Pro Gly Thr Leu Thr Gln Phe Gly Asn Thr Leu Asp Ser
 1185 1190 1195 1200
 Leu Tyr Gln Asp Trp Il Thr Tyr Pro Thr Thr Pro Glu Ala Arg Thr
 1205 1210 1215
 Thr Arg Trp Thr Arg Thr Trp Gln Lys Thr Lys Asn Ser Trp Ser Ser

1220	1225	1230
Phe Val Gln Val Phe Asp Gly Gly Asn Pro Pro Gln Pro Ser Asp Il		
1235	1240	1245
Gly Ala Leu Pro Ser Asp Asn Ala Thr Met Gly Asn Leu Thr Ile Arg		
1250	1255	1260
Asp Phe Leu Arg Ile Gly Asn Val Arg Ile Val Pro Asp Pro Val Asn		
1265	1270	1275
1280		
Lys Thr Val Lys Phe Glu Trp Val Glu		
1285		

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 65 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacteriophage T4
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ORF X amino acid
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Glu Lys Phe Met Ala Glu Ile Trp Thr Arg Ile Cys Pro Asn Ala		
1	5	10
Ile Leu Ser Glu Ser Asn Ser Val Arg Tyr Lys Ile Ser Ile Ala Gly		
20	25	30
Ser Cys Pro Leu Ser Thr Ala Gly Pro Ser Tyr Val Lys Phe Gln Asp		
35	40	45
Asn Pro Val Gly Ser Gln Thr Phe Arg Arg Arg Pro Ser Phe Lys Ser		
50	55	60
Phe		
65		

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 295 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacteriophage T4
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: p35 amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Leu Phe Arg Leu Gln Met Ile Leu His Gln Leu Leu Leu Val		
1	5	10
		15

Phe Met Asn Ser Leu Thr Asn Asn Arg Ile Val Ala Ile Leu Thr Ser
 20 25 30
 Gly Lys Val Asn Ph Pro Pro Glu Val Val Ser Trp Leu Arg Thr Ala
 35 40 45
 Gly Thr Ser Ala Phe Pro Ser Asp Ser Ile Leu Ser Arg Phe Asp Val
 50 55 60
 Ser Tyr Ala Ala Phe Tyr Thr Ser Ser Lys Arg Ala Ile Ala Leu Glu
 65 70 75 80
 His Val Lys Leu Ser Asn Arg Lys Ser Thr Asp Asp Tyr Gln Thr Ile
 85 90 95
 Leu Asp Val Val Phe Asp Ser Leu Glu Asp Val Gly Ala Thr Gly Phe
 100 105 110
 Pro Arg Arg Thr Tyr Glu Ser Val Glu Gln Phe Met Ser Ala Val Gly
 115 120 125
 Gly Thr Asn Asn Glu Ile Ala Arg Leu Pro Thr Ser Ala Ala Ile Ser
 130 135 140
 Lys Leu Ser Asp Tyr Asn Leu Ile Pro Gly Asp Val Leu Tyr Leu Lys
 145 150 155 160
 Ala Gln Leu Tyr Ala Asp Ala Asp Leu Leu Ala Leu Gly Thr Thr Asn
 165 170 175
 Ile Ser Ile Arg Phe Tyr Asn Ala Ser Asn Gly Tyr Ile Ser Ser Thr
 180 185 190
 Gln Ala Glu Phe Thr Gly Gln Ala Gly Ser Trp Glu Leu Lys Glu Asp
 195 200 205
 Tyr Val Val Val Pro Glu Asn Ala Val Gly Phe Thr Ile Tyr Ala Gln
 210 215 220
 Arg Thr Ala Gln Ala Gly Gln Gly Gly Met Arg Asn Leu Ser Phe Ser
 225 230 235 240
 Glu Val Ser Arg Asn Gly Gly Ile Ser Lys Pro Ala Glu Phe Gly Val
 245 250 255
 Asn Gly Ile Arg Val Asn Tyr Ile Cys Glu Ser Ala Ser Pro Pro Asp
 260 265 270
 Ile Met Val Leu Pro Thr Gln Ala Ser Ser Lys Thr Gly Lys Val Phe
 275 280 285
 Gly Gln Glu Phe Arg Glu Val
 290 295

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 221 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Bacteriophage T4

(vii) IMMEDIATE SOURCE:

(B) CLONE: p36 amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

M t Ala Asp Leu Lys Val Gly Ser Thr Thr Gly Gly Ser Val Ile Trp
1      5      10      15
His Gln Gly Asn Phe Pro Leu Asn Pro Ala Gly Asp Asp Val Leu Tyr
20      25      30
Lys Ser Phe Lys Ile Tyr Ser Glu Tyr Asn Lys Pro Gln Ala Ala Asp
35      40      45
Asn Asp Phe Val Ser Lys Ala Asn Gly Gly Thr Tyr Ala Ser Lys Val
50      55      60
Thr Phe Asn Ala Gly Ile Gln Val Pro Tyr Ala Pro Asn Ile Met Ser
65      70      75      80
Pro Cys Gly Ile Tyr Gly Gly Asn Gly Asp Gly Ala Thr Phe Asp Lys
85      90      95
Ala Asn Ile Asp Ile Val Ser Trp Tyr Gly Val Gly Phe Lys Ser Ser
100     105     110
Phe Gly Ser Thr Gly Arg Thr Val Val Ile Asn Thr Arg Asn Gly Asp
115     120     125
Ile Asn Thr Lys Gly Val Val Ser Ala Ala Gly Gln Val Arg Ser Gly
130     135     140
Ala Ala Ala Pro Ile Ala Ala Asn Asp Leu Thr Arg Lys Asp Tyr Val
145     150     155     160
Asp Gly Ala Ile Asn Thr Val Thr Ala Asn Ala Asn Ser Arg Val Leu
165     170     175
Arg Ser Gly Asp Thr Met Thr Gly Asn Leu Thr Ala Pro Asn Phe Phe
180     185     190
Ser Gln Asn Pro Ala Ser Gln Pro Ser His Val Pro Arg Phe Asp Gln
195     200     205
Ile Val Ile Lys Asp Ser Val Gln Asp Phe Gly Tyr Tyr
210     215     220

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1026 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Bacteriophage T4

(vii) IMMEDIATE SOURCE:

- (B) CLONE: p37 amino acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Ala Thr Leu Lys Gln Ile Gln Ph Lys Arg Ser Lys Ile Ala Gly
1      5      10      15

```

Thr Arg Pro Ala Ala Ser Val Leu Ala Glu Gly Glu Leu Ala Ile Asn
 20 25 30
 Leu Lys Asp Arg Thr Ile Phe Thr Lys Asp Asp Ser Gly Asn Ile Ile
 35 40 45
 Asp Leu Gly Phe Ala Lys Gly Gly Gln Val Asp Gly Asn Val Thr Il
 50 55 60
 Asn Gly Leu Leu Arg Leu Asn Gly Asp Tyr Val Gln Thr Gly Gly Met
 65 70 75 80
 Thr Val Asn Gly Pro Ile Gly Ser Thr Asp Gly Val Thr Gly Lys Ile
 85 90 95
 Phe Arg Ser Thr Gln Gly Ser Phe Tyr Ala Arg Ala Thr Asn Asp Thr
 100 105 110
 Ser Asn Ala His Leu Trp Phe Glu Asn Ala Asp Gly Thr Glu Arg Gly
 115 120 125
 Val Ile Tyr Ala Arg Pro Gln Thr Thr Thr Asp Gly Glu Ile Arg Leu
 130 135 140
 Arg Val Arg Gln Gly Thr Gly Ser Thr Ala Asn Ser Glu Phe Tyr Phe
 145 150 155 160
 Arg Ser Ile Asn Gly Gly Glu Phe Gln Ala Asn Arg Ile Leu Ala Ser
 165 170 175
 Asp Ser Leu Val Thr Lys Arg Ile Ala Val Asp Thr Val Ile His Asp
 180 185 190
 Ala Lys Ala Phe Gly Gln Tyr Asp Ser His Ser Leu Val Asn Tyr Val
 195 200 205
 Tyr Pro Gly Thr Gly Glu Thr Asn Gly Val Asn Tyr Leu Arg Lys Val
 210 215 220
 Arg Ala Lys Ser Gly Gly Thr Ile Tyr His Glu Ile Val Thr Ala Gln
 225 230 235 240
 Thr Gly Leu Ala Asp Glu Val Ser Trp Trp Ser Gly Asp Thr Pro Val
 245 250 255
 Phe Lys Leu Tyr Gly Ile Arg Asp Asp Gly Arg Met Ile Ile Arg Asn
 260 265 270
 Ser Leu Ala Leu Gly Thr Phe Thr Thr Asn Phe Pro Ser Ser Asp Tyr
 275 280 285
 Gly Asn Val Gly Val Met Gly Asp Lys Tyr Leu Val Leu Gly Asp Thr
 290 295 300
 Val Thr Gly Leu Ser Tyr Lys Lys Thr Gly Val Phe Asp Leu Val Gly
 305 310 315 320
 Gly Gly Tyr Ser Val Ala Ser Ile Thr Pro Asp Ser Phe Arg Ser Thr
 325 330 335
 Arg Lys Gly Ile Phe Gly Arg Ser Glu Asp Gln Gly Ala Thr Trp Ile
 340 345 350
 Met Pr Gly Thr Asn Ala Ala Leu Leu Ser Val Gln Thr Gln Ala Asp
 355 360 365
 Asn Asn Asn Ala Gly Asp Gly Gln Thr His Ile Gly Tyr Asn Ala Gly

370					375					380					
Gly 385	Lys	Met	Asn	His	Tyr 390	Phe	Arg	Gly	Thr	Gly 395	Gln	Met	Asn	Ile	Asn 400
Thr	Gln	Gln	Gly	Met 405	Glu	Ile	Asn	Pro	Gly 410	Ile	Leu	Lys	Leu	Val	Thr 415
Gly	Ser	Asn	Asn 420	Val	Gln	Phe	Tyr	Ala 425	Asp	Gly	Thr	Ile	Ser	Ser	Ile 430
Gln	Pro	Ile	Lys	Leu	Asp	Asn	Glu	Ile	Phe	Leu	Thr	Lys	Ser	Asn	Asn 445
Thr 450	Ala	Gly	Leu	Lys	Phe	Gly 455	Ala	Pro	Ser	Gln	Val	Asp	Gly	Thr	Arg 460
Thr 465	Ile	Gln	Trp	Asn	Gly 470	Gly	Thr	Arg	Glu	Gly 475	Gln	Asn	Lys	Asn	Tyr 480
Val	Ile	Ile	Lys	Ala 485	Trp	Gly	Asn	Ser	Phe 490	Asn	Ala	Thr	Gly	Asp	Arg 495
Ser	Arg	Glu	Thr 500	Val	Phe	Gln	Val	Ser 505	Asp	Ser	Gln	Gly	Tyr 510	Tyr	Phe 515
Tyr	Ala	His 515	Arg	Lys	Ala	Pro	Thr	Gly 520	Asp	Glu	Thr	Ile 525	Gly	Arg	Ile 530
Glu 530	Ala	Gln	Phe	Ala	Gly	Asp 535	Val	Tyr	Ala	Lys	Gly 540	Ile	Ile	Ala	Asn 545
Gly 545	Asn	Phe	Arg	Val	Val 550	Gly	Ser	Ser	Ala	Leu 555	Ala	Gly	Asn	Val	Thr 560
Met	Ser	Asn	Gly	Leu 565	Phe	Val	Gln	Gly	Gly 570	Ser	Ser	Ile	Thr	Gly	Gln 575
Val	Lys	Ile	Gly 580	Gly	Thr	Ala	Asn	Ala 585	Leu	Arg	Ile	Trp	Asn	Ala	Glu 590
Tyr	Gly	Ala 595	Ile	Phe	Arg	Arg	Ser	Glu 600	Ser	Asn	Phe	Tyr 605	Ile	Ile	Pro 610
Thr 610	Asn	Gln	Asn	Glu	Gly 615	Glu	Ser	Gly	Asp	Ile	His 620	Ser	Ser	Leu	Arg 625
Pro 625	Val	Arg	Ile	Gly	Leu 630	Asn	Asp	Gly	Met	Val 635	Gly	Leu	Gly	Arg	Asp 640
Ser	Phe	Ile	Val	Asp 645	Gln	Asn	Asn	Ala	Leu 650	Thr	Thr	Ile	Asn	Ser	Asn 655
Ser	Arg	Ile	Asn 660	Ala	Asn	Phe	Arg	Met 665	Gln	Leu	Gly	Gln	Ser 670	Ala	Tyr 675
Ile	Asp	Ala 675	Glu	Cys	Thr	Asp	Ala	Val 680	Arg	Pro	Ala	Gly 685	Ala	Gly	Ser 690
Phe 690	Ala	Ser	Gln	Asn	Asn	Glu 695	Asp	Val	Arg	Ala	Pro	Phe	Tyr	Met	Asn 700
Ile 705	Asp	Arg	Thr	Asp	Ala 710	Ser	Ala	Tyr	Val	Pro 715	Ile	Leu	Lys	Gln	Arg 720
Tyr	Val	Gln	Gly	Asn 725	Gly	Cys	Tyr	Ser	Leu 730	Gly	Thr	Leu	Ile	Asn	Asn 735

Gly Asn Phe Arg Val His Tyr His Gly Gly Gly Asp Asn Gly Ser Thr
 740 745 750
 Gly Pro Gln Thr Ala Asp Phe Gly Trp Glu Phe Il Lys Asn Gly Asp
 755 760 765
 Phe Ile Ser Pro Arg Asp Leu Ile Ala Gly Lys Val Arg Phe Asp Arg
 770 775 780
 Thr Gly Asn Ile Thr Gly Gly Ser Gly Asn Phe Ala Asn Leu Asn Ser
 785 790 795 800
 Thr Ile Glu Ser Leu Lys Thr Asp Ile Met Ser Ser Tyr Pro Ile Gly
 805 810 815
 Ala Pro Ile Pro Trp Pro Ser Asp Ser Val Pro Ala Gly Phe Ala Leu
 820 825 830
 Met Glu Gly Gln Thr Phe Asp Lys Ser Ala Tyr Pro Lys Leu Ala Val
 835 840 845
 Ala Tyr Pro Ser Gly Val Ile Pro Asp Met Arg Gly Gln Thr Ile Lys
 850 855 860
 Gly Lys Pro Ser Gly Arg Ala Val Leu Ser Ala Glu Ala Asp Gly Val
 865 870 875 880
 Lys Ala His Ser His Ser Ala Ser Ala Ser Ser Thr Asp Leu Gly Thr
 885 890 895
 Lys Thr Thr Ser Ser Phe Asp Tyr Gly Thr Lys Gly Thr Asn Ser Thr
 900 905 910
 Gly Gly His Thr His Ser Gly Ser Gly Ser Thr Ser Thr Asn Gly Glu
 915 920 925
 His Ser His Tyr Ile Glu Ala Trp Asn Gly Thr Gly Val Gly Gly Asn
 930 935 940
 Lys Met Ser Ser Tyr Ala Ile Ser Tyr Arg Ala Gly Gly Ser Asn Thr
 945 950 955 960
 Asn Ala Ala Gly Asn His Ser His Thr Phe Ser Phe Gly Thr Ser Ser
 965 970 975
 Ala Gly Asp His Ser His Ser Val Gly Ile Gly Ala His Thr His Thr
 980 985 990
 Val Ala Ile Gly Ser His Gly His Thr Ile Thr Val Asn Ser Thr Gly
 995 1000 1005
 Asn Thr Glu Asn Thr Val Lys Asn Ile Ala Phe Asn Tyr Ile Val Arg
 1010 1015 1020
 Leu Ala
 1025

What is claimed is:

1. An isolated polypeptide consisting essentially of the gp37 tail fiber protein of bacteriophage T4 lacking amino acids 99-496 (SEQ ID NO:6) when numbered from the amino terminus, wherein said polypeptide has the capability to form dimers and interact with the P36 protein oligomer of bacteriophage T4.
2. An isolated polypeptide consisting essentially of a fusion protein between the gp36 and gp37 proteins of bacteriophage T4, wherein amino acid residues 1-242 of gp37 (SEQ ID NO:6) are fused in proper reading frame to amino acid residues 118-221 of gp36 (SEQ ID NO:5).
3. The polypeptide of claim 2 wherein a plurality of carboxy termini of said polypeptide have the capability of interacting with the amino terminus of the P37 protein oligomer of bacteriophage T4 and to form an attached oligomer and the amino termini of the oligomer of said polypeptide have the capability of interacting with the carboxy termini of gp36 polypeptides of bacteriophage T4.
4. An isolated polypeptide oligomer consisting essentially of two gp37 polypeptides of bacteriophage T4, wherein the amino termini of said oligomer lack the capability of interacting with the carboxy termini of gp36 polypeptides of bacteriophage T4.
5. An isolated polypeptide oligomer consisting essentially of the P37 protein of bacteriophage T4, wherein the amino termini of said oligomer lack the capability of interacting with the carboxy termini of gp36 polypeptides of bacteriophage T4.
6. An isolated polypeptide consisting essentially of a variant of the gp36 protein of bacteriophage T4, wherein

said polypeptid lacks the capability of interacting with the amino t rminus of the P37 protein oligomer of bacteriophage T4.

5 7. An isolated polypeptide consisting essentially of a fusion protein between the gp36 and gp34 proteins of bacteriophage T4, wherein amino acid residues 1-73 of gp36 (SEQ ID NO:5) are fused in proper reading frame amino-terminal to amino acid residues 866-1289 of gp34 (SEQ
10 ID NO:2).

8. An oligomer of the polypeptide of claim 7, wherein the amino termini of said dimer have the capability of interacting with the gp35 protein of bacteriophage T4.
15

9. An isolated polypeptide consisting essentially of a variant of the gp35 protein of bacteriophage T4, wherein said polypeptide forms an angle of less than about 125° when combined with the P34 and P36-P37 protein oligomers of
20 bacteriophage T4, under conditions wherein the wild-type gp35 protein forms an angle of 137° when combined with said oligomers.

10. An isolated polypeptide consisting essentially
25 of a variant of the gp35 protein of bacteriophage T4, wherein said polypeptide forms an angle of more than about 145° when combined with the P34 and P36-P37 protein oligomers of bacteriophage T4, under conditions wherein the wild-type gp35 protein forms an angle of 137° when combined with said
30 oligomers.

11. An isolated polypeptide consisting essentially of a variant of the gp35 protein of bacteriophage T4, wherein the interaction of said polypeptide with the P34 protein
35 oligomer of bacteriophage T4 is unstable at temperatures b tween about 40°C and about 60°C.

12. An isolated polypeptide oligomer consisting essentially of a variant of the P37 protein of bacteriophage T4, wherein the interaction of said oligomer with the P36 protein oligomer of bacteriophage T4 is unstable at 5 temperatures between about 40°C and about 60°C.

13. An isolated polypeptide oligomer consisting essentially of a variant of the P37 protein of bacteriophage T4, wherein the carboxy-terminal domain of said oligomer is 10 modified so as to confer the ability of the entire polypeptide to bind specifically to an immobilized ligand.

14. The polypeptide of claim 13, wherein said ligand is selected from the group consisting of biotin, 15 immunoglobulin, or divalent metal ions.

15. A nanostructure comprising a plurality of fusion proteins, said fusion proteins comprising a first portion consisting of at least the first 10 N-terminal amino 20 acids of a tail fiber protein fused via a peptide bond to a second portion consisting of at least the last 10 C-terminal amino acids of a second tail fiber protein, wherein the tail fiber proteins are selected from the group consisting of gp34, gp35, gp36, and gp37 proteins of a T-even-like 25 bacteriophage, wherein the first and second tail fiber proteins are the same or different.

16. The nanostructure of claim 15, wherein the first and second tail fiber proteins are different. 30

17. The nanostructure of claim 15, which further comprises a molecule that can self-assemble into a dimer or trimer, fused to at least a 10 amino acid portion of a T-even-like tail fiber protein. 35

18. The nanostructure of claim 17, wherein the molecule has the structure of a leucine zipper.

19. The nanostructure of claim 15, wherein said nanostructure comprises a linear one-dimensional rod.

20. The nanostructure of claim 15, wherein said nanostructure comprises a polygon.

21. The nanostructure of claim 15, wherein said nanostructure comprises a three-dimensional cage or solid.

22. The nanostructure of claim 15, wherein said nanostructure comprises a two-dimensional open or closed sheet.

23. An isolated fusion protein consisting essentially of a portion of a gp37 protein of a T-even-like bacteriophage consisting of at least the first 10-60 N-terminal amino acids of the gp37 protein fused to a second portion of a gp36 protein of a T-even-like bacteriophage consisting of at least the last 10-60 C-terminal amino acids of the gp36 protein.

24. An isolated fusion protein consisting essentially of a portion of a gp37 protein of a T-even-like bacteriophage consisting of at least the first 10 N-terminal amino acids of the gp37 protein fused to a second portion of a gp36 protein of a T-even-like bacteriophage consisting of at least the last 10 C-terminal amino acids of the gp36 protein.

25. An isolated fusion protein consisting essentially of a portion of a gp37 protein of a T-even-like bacteriophage consisting of at least the first 20 N-terminal amino acids of the gp37 protein fused to a second portion of a gp36 protein of a T-even-like bacteriophage consisting of at least the last 20 C-terminal amino acids of the gp36 protein.

26. An isolated fusion protein consisting essentially of a portion of a gp36 protein of a T-even-like bacteriophage consisting of at least the first 10-60 N-terminal amino acids of the gp36 protein fused to a second portion of a gp34 protein of a T-even-like bacteriophage consisting of at least the last 10-60 C-terminal amino acids of the gp34 protein.

27. An isolated protein comprising at least 20 contiguous amino acids of the gp37, gp36, or gp34 protein of a T-even-like bacteriophage, and lacking at least 5 amino acids of the amino- or carboxy-terminus of the protein.

28. An isolated DNA encoding the polypeptide of claim 1.

29. An isolated DNA encoding the polypeptide of claim 2.

30. An isolated DNA encoding the polypeptide of claim 4.

31. An isolated DNA encoding the polypeptide of claim 5.

32. An isolated DNA encoding the polypeptide of claim 6.

33. An isolated DNA encoding the polypeptide of claim 7.

34. An isolated DNA encoding the polypeptide of claim 9.

35. An isolated DNA encoding the polypeptide of claim 10.

36. An isolated DNA encoding the polypeptide of claim 11.

37. An isolated DNA encoding the polypeptide of claim 12.

38. An isolated DNA encoding the polypeptide of claim 13.

39. An isolated DNA encoding the protein of claim 23.

40. An isolated DNA encoding the protein of claim 25.

41. An isolated DNA encoding the protein of claim 26.

42. An isolated DNA encoding the protein of claim 27.

43. A method for making a polygonal nanostructure comprising contacting the protein of claim 26 with purified gp35 proteins of a T-even-like bacteriophage.

44. A method for making a nanostructure comprising contacting a plurality of the proteins of claim 23 with each other.

45. A kit comprising in one or more containers the fusion protein of claim 23.

46. A kit comprising in one or more containers the fusion protein of claim 25.

47. A kit comprising in one or more containers the fusion protein of claim 26.

48. A kit comprising in one or more containers the fusion protein of claim 26, and an isolated gp35 protein of a T- v n-lik bact riophag .

5 49. The protein of claim 23 wherein the T-even-like bacteriophage is T4.

50. The protein of claim 26 wherein the T-even-like bacteriophage is T4.

10

51. An isolated polypeptide consisting essentially of a variant of the gp36 protein of bacteriophage T4, wherein the interaction of said polypeptide with the P37 protein oligomer of bacteriophage T4 is unstable at temperatures
15 between about 40°C and about 60°C.

52. An isolated polypeptide consisting essentially of a variant of the gp36 protein of bacteriophage T4, wherein the interaction of said polypeptide with the gp35 protein of
20 bacteriophage T4 is unstable at temperatures between about 40°C and about 60°C.

53. An isolated polypeptide consisting essentially of a variant of the gp34 protein of bacteriophage T4, wherein
25 the interaction of said polypeptide with the gp35 protein of bacteriophage T4 is unstable at temperatures between about 40°C and about 60°C.

30

35

FIG. 1A




FIG. 1B





FIG. 2

$$B \Rightarrow F$$

...>==>>==>>==>>==>>==>...

FIG. 3A




FIG. 3B




FIG. 3D

8471-005 (SHEET 7 OF 19)




FIG. 4




FIG. 5

8471-005 (SHEET 9 OF 19)

T4 Genes 34-37 seq -> List

DNA sequence 8855 b.p. TAGGAGCCCGGG ... CGGCCCTTCTAA linear

Gene34:bp16-3885; OrfX:bp2894-4091; Gene35:bp4127-5014; Gene36:bp5077-5742; Gene 37:bp5751-8831.

	10	20	30	40	50	60
1	TAGGAGCCCG	GGAGAAATGGC	CGAGATTAAA	AGAGAATTCA	GAGCAGAAGA	TGGTCTGGAC 60
61	GCAGGTGGTG	ATAAAAAAT	CAACGTAGCT	TTAGCTGATC	GTACCGTAGG	AACTGACGGT 120
121	GTTAACGGTG	ATTACTTAAT	TCAAGAAAAC	ACAGTTCAAC	AGTATGATCC	AACTCGTGGG 180
181	TATTTAAAAG	ATTTTGTAAAT	CATTTATGAT	AACCGCTTTT	GGCGTGCTAT	AAATGATATT 240
241	CCAAAACAG	CAGGAGCTTT	TAATAGCGGA	CGCTGGAGAG	CATTACGTAC	CGATGCTAAC 300
301	TGGATTACGG	TTTCATCTGG	TTTCATATCAA	TTAAAAATCTG	GTGAAGCAAT	TTGGGTTAAC 360
361	ACCGCAGCTG	GAAATGACAT	CACGTTTACT	TTACCATCTT	CTCCAAATTGA	TGGTGATACT 420
421	ATCGTTCCTC	AAGATATTGG	AGGAAAACCT	GGAGTTAAC	AAATTTTAAAT	TGTAGCTCCA 480
481	GTACAAAGTA	TGTAAACTT	TAGAGGTGAA	CAGGTACGTT	CAGTACTAAT	GACTCATCCA 540
541	AGTCACAGC	TAGTTTAAAT	TTTTAGTAAT	CGTCTGTGGC	AAATGTATGT	TGCTGATATT 600
601	AGTAGAGAA	CTATAGTTGT	AACACCAGCG	AATACTTATC	AAAGCGCAATC	CAACGATTTT 660
661	ATCGTAGCTA	GATTTACTTC	TGCTGCACCA	ATTAATGTCA	AACTTCCAAG	ATTTGCTAAT 720
721	CATGGCGATA	TTATTAATTT	CGTCGATTTA	GATAAACTAA	ATCCGCTTTA	TCATACAAAT 780
781	GTTACTACAT	ACGATGAAAC	GACTTCAGTA	CAAGAAGTTG	GAATCTATT	CATTGAAGGC 840
841	CGTACATCGA	TTCAGCGTTT	CTTGATGTTT	GATGATAATG	AGAAATTATG	GAGACTGTTT 900
901	GACGGGGATA	GTAAGAGCGG	TTTACGTATC	ATAACGACTA	ATTCAAACAT	TGCTCCAAAT 960
961	GAAGAAGTTA	TGGTATTTCG	TGCGAATAAC	GGAAACAATC	AAACAATTGA	GCTTAAGCTT 1020
1021	CCAACTAATA	TTTCTGTGTT	TGATACGTGT	AAAAATTTCCA	TGAATTACAT	GAGAAAAGGA 1080
1081	CAAAACAGTA	AAATCAAAAG	TGCTGATGAA	GATAAAATTG	CTTCTTCAGT	TCAATTGCTG 1140
1141	CAATTCCTCA	AACGCTCAGA	ATATCCACCT	GAAGCTGAAT	GGGTACAGT	TCAAGAAATTA 1200
1201	GTTTPTAACG	ATGAAACTAA	TTATGTTCCA	GTTTGGAGC	TTGCTTACAT	AGAAGATTCT 1260
1261	GATGGAAAAT	ATTGGGTTGT	ACAGCAAAAC	GTTTCCAAGT	TAGAAAGAGT	AGATTCTTTA 1320
1321	AATGATTCTA	CTAGAGCAAG	ATTAGGCGTA	ATTGCTTTAG	CTACACAAGC	TCAAGCTAAT 1380
1381	GTGATTTTAA	AAAATTTCTC	ACAAAAGAA	TTAGCAATTA	CTCCAGAAAC	GTTAGCTAAT 1440
1441	CGTACTGCTA	CAGAAACTCG	CAGAGGTATT	GCAAGAAATG	CAACTACTGC	TCAAGTGAAT 1500
1501	CAGAACACCA	CATTCTCTTT	TGCTGATGAT	ATTATCATCA	CTCCTAAAAA	GCTGAATGAA 1560
1561	AGAACTGCTA	CAGAAACTCG	TAGAGGTGTC	GCAGAAATTG	CTACGCAGCA	AGAAACTAAT 1620
1621	GCAGGAACCG	ATGATACATC	AACTCATCACT	CCTAAAAAGC	TTCAAGCTCG	TCAAGGTTCCT 1680
1681	GAATCATTAT	CTGCTATTGT	AACCTTTGTA	TCTACTGCAG	GTGCTACTCC	AGCTTCTAGC 1740
1741	CGTGAAATTA	ATGTTACGAA	TGTTTATAAT	AAAAACACTG	ATAATTTAGT	TGTTTCACCT 1800
1801	AAAGCTTTGG	ATCAGTATAA	AGCTACTCCA	ACACAGCAAG	GTGCAAGTAAT	TTTAGCAGTT 1860
1861	GAAAGTGAAG	TAATTGCTGG	ACAAAGTCAG	CAAGGATGGG	CAAAATGCTGT	TGTAACGCCA 1920
1921	GAAACGTTAC	ATAAAAAGAC	ATCAACTGAT	GGAAGAATTG	GTTTAATTGA	AAATTGCTACG 1980
1981	CAAGATGAAG	TTAATACAGG	AACTGATTAT	ACTCGTGACG	TCACTCTCTA	AACTTTAAAT 2040
2041	GACCGTAGAG	CAACTGAAAG	TTTAAGTGGT	ATAGCTGAAA	TTGCTACACA	AGTTGAATTC 2100
2101	GACGCAGGCG	TGCAAGATAC	TGCTATCTCT	ACACCATTTA	AAATTAATAAC	CAGATTTAAT 2160
2161	AGTACTGATC	GTACTTCTGT	TGTTGCTCTA	TCTGGATTAG	TTGAATCAGG	AACTCTCTGG 2220
2221	GACCATTTATA	CATTAAATAT	TCTTGAAGCA	AATGAGACAC	AACGTGGTAC	ACTTCTGTGA 2280
2281	GCTACCGCAG	TGCAAGCTGC	TGCGGGAACA	TTAGATAATG	TTTTAATAAC	TCCTAAAAAG 2340
2341	CTTTTATAGTA	CTAAATCTAC	TGAAGCGCAA	GAGGGTGTTA	TTAAAGTTGC	AACTCAGTCT 2400
2401	GAAACTGTGA	CTGGAACGTC	AGCAAACTAT	GCTGTATCTC	CAAAAAATTT	AAAAATGATT 2460
2461	GCGCAGAGTG	AACCTACTTG	GGCAGCTACT	ACTGCAATAA	GAGGTTTTGT	TAAAACTTCA 2520
2521	TCTGGTTCAA	TTACATTCGT	TGGTAATGAT	ACAGTCGGTT	CTACCCAAGA	TTTAGAACTG 2580
2581	TATGAGAAAA	ATAGCTATGC	GGTATCACCA	TATGAATTAA	ACCGTGTATT	AGCAAAATTA 2640
2641	TTGCCACTAA	AAGCAAAAGC	TGCTGATACA	AAATTTATTG	ATGCTCTAGA	TTTATCTCAG 2700
2701	TTTATTCGTA	GGGATATTGC	ACAGACGGTT	AATGGTTTAC	TAACCTTAAC	CCAACAAACG 2760
2761	AACTGTAGTG	CCCCCTCTGT	ATCATCTAGT	ACTGGTGAAT	TTGGTGGTTC	ATTGGCCGCT 2820
2821	AAATAGAACAT	TTACCATCCG	TAATACAGGA	GCCCCGACTA	GTATCGTTTT	CGAAAAAGGT 2880
2881	CCTGCATCCG	GGGCAAAATC	TGCACAGTCA	ATGAGTATTTC	GTGTATGGGG	TAACCAATTT 2940
2941	GGCGGCGGTA	GTGATACGAC	CCGTTCGACA	GTGTTTGAAG	TTGGCGATGA	CACATCTCAT 3000
3001	CACTTTTATT	CTCAACGTAA	TAAAGACGGT	AAATATAGCT	TTAACAATTAA	TGGTACTGTA 3060
3061	ATGCCAATAA	ACATTAAATG	TTCCGGTTTG	ATGAATGTGA	ATGGCACTGC	AACATTCCGGT 3120
3121	CGTTCAGTTA	CAGCCAAATG	TGAATTCAATC	AGCAAGTCTG	CAAAATGCTTT	TAGAGCAATA 3180
3181	AACGGTGATT	ACCGATTCTT	TATTCGTAAT	GATGCCTCTA	ATACCTATTT	TTTGCTCACT 3240
3241	GCAGCCGGTG	ATCAGACTGG	TGGTTTTAAAT	GGATTACGCC	CATTATTAAAT	TAATAATCAA 3300
3301	TCCGGTCAGA	TTACAAATGG	TGAAGGCTTA	ATCATTTGCCA	AAGGTGTTAC	TATAAATTTCA 3360
3361	GGCGGTTTTA	CTGTTAACTC	GAGAAATTCGT	TCTCAGGGTA	CTAAAAATC	TGATTTTATAT 3420
3421	ACCCGTGCGC	CAACATCTGA	TACTGTAGGA	TTCTGGTCAA	TGATATTAA	TGATTCAGCC 3480
3481	ACTTATAACC	AGTTCCCGGG	TTATTTTAAA	ATGGTTGAAA	AAACTAAATGA	AGTGACTGGG 3540
3541	CTTCCATACT	TAGAAAGCTG	CGAAGAAGTT	AAATCTCTG	GTACACTGAC	TCAGTTTGGT 3600
3601	AACACACTTG	ATTCCGTTTA	CCAAGATTGG	ATTACTTATC	CAACGACGCC	AGAAGCGCGT 3660
3661	ACCCTCTGCT	GGACACGTAC	ATGGCAGAAA	ACCAAAAACT	CTTGGTCAAG	TTTTGTTTCA 3720
3721	GTATTTGACG	GAGGTAACCC	TCTTCAACCA	TCTGATATCG	GTGCTTTACC	ATCTGATAAT 3780
3781	GCTACAAATG	GGAATCTTAC	TATTCGTGAT	TTCTTGGCAA	TTGGTAATGT	TCCGATTGTT 3840
3841	CCTGACCCAG	TGAATAAAAC	GGTTAAATTT	GAATGGGTTG	AATAAGAGGT	ATTATGAAA 3900

FIG. 6

14 Genes 34-37 seq -> List

```
3901 AATTTATGGC CGAGATTGGG ACAAGGATAT GTCCAAACGC CATTTTATCG GAAAGTAATT 3960
3961 CAGTAAGATA TAAAATAAGT ATAGCGGGTT CTGCGCCGCT TTCTACACGA GGACCATCAT 4020
4021 ATGTTTAAAT TCAGGATAAT CCTGTAGGAA GTCAAACATT TAGGCGCAGG CCTTCATTTA 4080
4081 AGAGTTTTCG ACCCTTCCAC CGGAGCATTA GTTGATAGTA AGTCATATGC TTTTTCGACT 4140
4141 TCAAATGATA CTACATCAGC TGCTTTTGTT AGTTTTTCATG AATTCCTTGA CGAATAATCG 4200
4201 AATTGTGCTT ATATTAACTA GTGGAAAGGT TAATTTTCCT CCGTGAAGTAG TATCTTGOTT 4260
4261 AAGAACCCTC GGAACGCTCT; CCTTTCCATC TGATTCTATA TTGTCAAGAT TTGACGTATC 4320
4321 ATATGCTGCT TTTTATACIT CTCTCTAAAG AGCTATCGCA TTAGAGCATG TTAACCTGAG 4380
4381 TAATAGAAAA AGCAGAGATG ATTATCAAAC TATTTTAGAT GTTGTATTGG ACAGTTTAGA 4440
4441 AGATGTAGGA GCTACCGGGT TTCCAAGAAG AACGTATGAA AGTGTGAGC AATTCATGTC 4500
4501 GGCAGTTGGT GGAACATAA ACGAAATTGC GAGATTGGCA ACTTCAGCTG CTATAAGTAA 4560
4561 AATGCTGATG TATTAATTAA TTCTGGAGA TATTTTAGAT GTTGTATTGG ACAGTTTAGA 4620
4621 TGATGCTGAT TTAATTGCTC TTGGAACATC AAATATATCT ATCCGTTTTT ATAATGCATC 4680
4681 TAACGGATAT ATTTCTTCAA CACAAGCTGA ATTTACTGGG CAAGCTGGGT CATGGGAATT 4740
4741 AAGGGAAGAT ATATTAGTTG TTCCAGAAA CGCAGTAGGA TTTACGATAT ACGCACAGAG 4800
4801 AACTGCACAA GCTGGCCAAG GTGGCATGAG AAATTTAAGC TTTTCTGAAG TATCAAGAAA 4860
4861 TGGCGGCATT TCGAAACCTG CTGAATTGG CGTCAATGGT ATTCGTGTTA ATTATATCTG 4920
4921 CGAATCCGCT TCACCTCCGG ATATAATGGT ACTTCTACG CAAGCATCGT CTAAAACTGG 4980
4981 TAAAGTGTTC GGGCAAGAAT TTAGAGAAGT TTAATTTGAG GGACCCCTCG GGTTCCTTTT 5040
5041 TTTCTTTATA ATCTATTCA AATAAAGGGG CATACAAATG CTGATTTAAA AGTAGGTTCA 5100
5101 ACAACTGGAG GTCCTGTCAT TTGGCATCAA GGAAATTTTC CATTGAATCC AGCCGGTGAC 5160
5161 GATGCTACTT ATAAATCATT TAAAATATAT TCAGAAATA ACAAAACACA AGCTGCTGAT 5220
5221 AACGATTTTC TTTCTAAAGC TAAATGGTGGT ACTTATGCAT CAAAGGTAAC ATTFAACGCT 5280
5281 GGCAATTCAG TCCCATATGC TCCAACATC ATGAGCCCAT GCGGGATTTA TGGGGTAAAC 5340
5341 GGTGATGGTG CTACTTTTGA TAAAGCAAAT ATCGATATTG TTTTATGTA TGGCGTAGGA 5400
5401 TTTAAATCGT CATTTGGTTC AACAGGCCGA ACTGTGTGTA TTAATACACG CAATGGTGAT 5460
5461 ATTAAACAAA AAGGTGTGTT GTCCGAGCT TATGTTGATG GAGCAATAAA TACTGTTACT 5520
5521 ATAGCAGCGA ATGACCTTAC TAGAAAGGAC GGTGACACCA TGACAGGTAA TTTAACAGCG 5580
5581 CCAATGCAA ACTCTAGGGT GCTACGGTCT GGTGACACCA TGACAGGTAA TTTAACAGCG 5640
5641 GCAAACTTTT TCTCGCAGAA TCCTGCATCT CAACCCCTAC ACCTTCCACG ATTTGACCAA 5700
5701 ATCGTAATTA AGGATTTCTG TCAAGATTTC GGCTATTATT AAGAGGACTT ATGGCTACTT 5760
5761 TAAACAAATG ACAATTTAAA AGAAGCAAAA TCGCAGGAAC ACCTCCTGCT GCTTCAGTAT 5820
5821 TAGCCGAAGT TGAATTTGGT ATAACTTAA AAGATAGAAC AATTTTACT AAAGATGATT 5880
5881 CAGGAAATAT CATCGATCTA GGTTTTGCTA AAGGCGGCA AGTTGATGGC AACGTTACTA 5940
5941 TTAACGGCAT TTTGAGATTA AATGGCGATT ATGTACAAC AGGTGGAAATG ACTGTAAACG 6000
6001 GACCAATTTG TTTCTACTGT GCGGTCACG GAAAAATTTT CAGATCTACA CAGGGTTTCA 6060
6061 TTTATGCAAG AGCAACAAAC GATACTTCAA ATGCCCATTT ATGGTTTGAA AATGCCGATG 6120
6121 GCACCTGAACG TGGCGTTATA TATGCTCGCC CTCAAACCTAC AACTGACGGT GAAATACGCC 6180
6181 TTAGGGTTAG TCAAGGAACA GGAAGCACTG CCAACAGTGA ATTTCTATTTC CGCTCTATAA 6240
6241 ATGGAGGCGA ATTTACGGCT AACCGTATTT TAGCATCAGA TTCTGTTAGTA ACAAACGCA 6300
6301 TTTCGGTTGA TCCCGTTATT CATGATGCCA AAGCATTTGG ACAATATGAT TCTCACTCTT 6360
6361 TGGTTAAITTA TGTTTATCCT GGAACCGGTG AAACAAATGG TGTAAACTAT CTTCTGTAAG 6420
6421 TTCCGCTTAA GTCCGGTGGT ACAATTTATC ATGAAATTCG TACTGCACAA ACAGGCTTGG 6480
6481 CTGATGAAGT TTCTTTGGTG TCTGGTGATA CACCAATATT TAAACTATAC GGTATTCTGT 6540
6541 ACGATGGCAG AATGATTATC GTTAATAGCC TTGCATTAGG TACATTCACT ACAAATTTTC 6600
6601 CGTCTAGTGA TTAATGGCAAC GTCCGGTGTA TGGGCGATAA GTATCTTGTG CTGCGGACA 6660
6661 CTGTAACTGC TTTGTCTATC AAAAAAAGT GTGTATTTGA TCTAGTTGGC GGTGGATATT 6720
6721 CTGTTGCTTC TATTACTCCT GACAGTTTCC GTAGTACTCG TAAAGGTATA TTTGGTCTGT 6780
6781 CTGAGGACCA AGGCGCAACT TGGATAATGC CTGGTACAAA TGCTGCTCTC TTGTCTGTTT 6840
6841 AAACACAAAG TGATAATTAAC AATGCTGGAG ACGGACAAAC CCATATCGGG TACAAATGCT 6900
6901 GCGGTAAATG GAACCACTAT TTCCGTGGTA CAGGTCAGAT GAAATATCAAT ACCCAACAAG 6960
6961 GTATGGAAT TAACCCGGGT ATTTTGAAAT TGGTAACTGG CTCTAATAAT GTACAAATTT 7020
7021 ACGCTGACCG AACTATTTC TCCATTCAAC CTATTAAATT AGATAACGAG ATATTTTTAA 7080
7081 CTAAATCTAA TAAATCTGCG GGTCTTAAAT TTGGAGCTCC TAGCCAAGTT GATGGCACA 7140
7141 GGAATATCCA ATGGAACGGT GGTACTCGCG AAGGACAGAA TAAAAACTAT GTGATTATTA 7200
7201 AAGCATGGGG TAACTCATTT AATGCCACTG GTGATAGATC TCGCGAAACG GTTTTCCAAG 7260
7261 TATCAGATAG TCAAGGATAT TATTTTATG CTCAATCGTA AGCTCCAAAC GCGCAGGAAA 7320
7321 CTATTGGACG TATTGAAGCT CAATTTGCTG GGGATGTTTA TGCTAAAGGT ATTATTGCCA 7380
7381 ACGGAAATTT TAGAGTTGTT GGGTCAAGCG CTTTAGCCGG CAATGTTACT ATGCTTAAAG 7440
7441 GTTTGTTTGT CCAAGGTGGT TCTTCTATTA CTGGACAAGT TAAATTTGGC GGAACAGCAA 7500
7501 ACGCACTGAG AATTTGGAAC GCTGAATATG GTGCTATTTT CCGTCTGTCG GAAAGTAACT 7560
7561 TTTATATTAT TCCAACCAAT CAAATGAAG GAGAAAGTGG AGACATTAC AGCTCTTTGA 7620
7621 GACCTGTGAG AATAGGATTA AACGATGCA TGGTTGGGTT AGGAAGAGAT TCTTTTATAG 7680
7681 TAGATCAAAA TAATGCTTTA ACTACGATA ACAGTAACTC TCGCATTAAT GCCAATTTA 7740
7741 GAAATGCAAT GGGCAGTCG GCATACATTG ATGCAGAAAT TACTGATGCT GTTCGCCCGG 7800
7801 CCGGTGCAAG TTCAATTTGCT TCCAGAAATA ATGAAGACGT CCGTGGCGCG TTCTATATGA 7860
7861 ATATTGATAG AACTGATGCT AGTGATATC TTCTATTTT GAAACAAAGT TATGTTCAAG 7920
7921 GCAATGGCTG CTATTCAATTA GGGACTTTAA TTAATAATGG TAAATTTCCG GTTCATTACC 7980
7981 ATGGCGGCGG AGATAACCGT TCTACAGGTC CACAGACTGC TGAATTTGGA TGGGAATTTA 8040
8041 TTAATAACCG TGATTTTATT TCACCTCGCG ATTTAATAGC AGGCAAGTC AGATTTGATA 8100
8101 GAACCTGGTA TATCACTGGT GGTTCCTGTA ATTTTGTCTA CTTAAACAGT ACAATTGAAT 8160
8161 CACTTAAACG TGATATCATG TCGAGTTACC CAATGGTGGC TCCGATTCCT TGGCGAGTC 8220
8221 ATTCAGTTCC TGCTGGATTT GCTTTGATGG AAGGTCAGAC CTTTGATTAAG TCCGCATATC 8280
8281 CAAAGTTAGC TGTGTCATAT CCTAGCGGTG TTATTCCAGA TATGGCGGGG CAAACTATCA 8340
```

FIG. 6 (CONT.)

8471-005 (SHEET // OF 19)

T4 Genes 34-37 seq -> List

8341	AGGOTAAACC	AAGTGGTCGT	GCTGTTTGA	GCGCTGAGGC	AGATGGTGTT	AAGGCTCATA	8400
8401	GCCATAGTGC	ATCGGCTTCA	AGTACTGACT	TAGGTACTAA	AACCACATCA	AGCTTTGACT	8460
8461	ATGGTACGAA	GGGAACAAAC	AGTACGGGTG	GACACACTCA	CTCTGGTAGT	GTTTCTACTA	8520
8521	GCACAAATGG	TGAGCACAGC	CACTACATCG	AGGCATOGAA	TGGTACTGGT	GTAGGTGGTA	8580
8581	ATAAGATGTC	ATCATATGCC	ATATCATACA	GGGCGGGTGG	GAGTAACACT	AATGCAGCAG	8640
8641	GGAACACAG	TCACTCTTTC	TCTTTTGGGA	CTAGCAGTGC	TGGCGACCAT	TCCCACTCTG	8700
8701	TAGGTATTGG	TGCTCATACC	CACACGGTAG	CAATTGGATC	ACATGGTCAT	ACTATCACTG	8760
8761	TAAATAGTAC	AGGTAATACA	GAAAACACCG	TTAAAAACAT	TGCTTTTAAC	TATATCGTTC	8820
8821	GTTTAGCATA	AGGAGAGGGG	CTTGGGCCCT	TCTAA			8855
	10	20	30	40	50	60	

FIG. 6 (CONT.)

T4 Genes 34-37 seq -> Genes

DNA sequence 8855 b.p. TAGGAGCCCGGG ... CGGCCCTTCTAA linear

Gene34:bp16-3885; orfX:bp3894-4091; Gene35:bp4127-5014; Gene36:bp5077-5742; Gene 37:bp5751-8831.

```

1 TAGGAGCCCGGGAGA ATG GCC GAG ATT AAA AGA GAA TTC AGA GCA GAA GAT GGT CTG GAC GCA 63
1      M A E I K R E F R A E D G L D A 16

64 GGT GGT GAT AAA ATA ATC AAC GTA GCT TTA GCT GAT CGT ACC GTA GGA ACT GAC GGT GTT 123
17 G G D K I I N V A L A D R T V G T D G V 36

124 AAC GTT GAT TAC TTA ATT CAA GAA AAC ACA GTT CAA CAG TAT GAT CCA ACT CGT GGA TAT 183
37 N V D Y L I Q E N T V Q Q Y D P T R G Y 56

184 TTA AAA GAT TTT GTA ATC ATT TAT GAT AAC CGC TTT TGG GCT GCT ATA AAT GAT ATT CCA 243
57 L K D F V I I Y D N R F W A A I N D I P 76

244 AAA CCA GCA GGA GCT TTT AAT AGC GGA CGC TGG AGA GCA TTA CGT ACC GAT GCT AAC TGG 303
77 K P A G A F N S G R W R A L R T D A N W 96

304 ATT ACG GTT TCA TCT GGT TCA TAT CAA TTA AAA TCT GGT GAA GCA ATT TCG GTT AAC ACC 363
97 I T V S S G S Y Q L K S G E A I S V N T 116

364 GCA GCT GGA AAT GAC ATC ACG TTT ACT TTA CCA TCT TCT CCA ATT GAT GGT GAT ACT ATC 423
117 A A G N D I T F T L P S S P I D G D T I 136

424 GTT CTC CAA GAT ATT GGA GGA AAA CCT GGA GTT AAC CAA GTT TTA ATT GTA GCT CCA GTA 483
137 V L Q D I G G K P G V N Q V L I V A P V 156

484 CAA AGT ATT GTA AAC TTT AGA GGT GAA CAG GTA CGT TCA GTA CTA ATG ACT CAT CCA AAG 543
157 Q S I V N F R G E Q V R S V L M T H P K 176

544 TCA CAG CTA GTT TTA ATT TTT AGT AAT CGT CTG TGG CAA ATG TAT GTT GCT GAT TAT AGT 603
177 S Q L V L I F S N R L W Q M Y V A D Y S 196

604 AGA GAA GCT ATA GTT GTA ACA CCA GCG AAT ACT TAT CAA GCG CAA TCC AAC GAT TTT ATC 663
197 R E A I V V T P A Q S N D F I 216

664 GTA CGT AGA TTT ACT TCT GCT GCA CCA ATT AAT GTC AAA CTT CCA AGA TTT GCT AAT CAT 723
217 V R R F T S A A P I N V K L P R F A N H 236

724 GGC GAT ATT ATT AAT TTC GTC GAT TTA GAT AAA CTA AAT CCG CTT TAT CAT ACA ATT CTT 783
237 G D I I N F V D L D K L N P L Y H T I V 256

784 ACT ACA TAC GAT GAA ACG ACT TCA GTA CAA GAA GTT GGA ACT CAT TCC ATT GAA GGC CGT 843
257 T T Y D E T T S V Q E V G T H S I E G R 276

844 ACA TCG ATT GAC GGT TTC TTG ATG TTT GAT GAT AAT GAG AAA TTA TGG AGA CTG TTT GAC 903
277 T S I D G F L M F D D N E K L W R L F D 296

904 GGG GAT AGT AAA GCG CGT TTA CGT ATC ATA ACG ACT AAT TCA AAC ATT CGT CCA AAT GAA 963
297 G D S K A R L R I I T T N S N I R P N E 316

964 GAA GTT ATG GTA TTT GGT GCG AAT AAC GGA ACA ACT CAA ACA ATT GAG CTT AAG CTT CCA 1023
317 E V M V F G A N N G T T Q T I E L K L P 336

1024 ACT AAT ATT TCT GTT GGT GAT ACT GTT AAA ATT TCC ATG AAT TAC ATG AGA AAA GGA CAA 1083
337 T N I S V G D T V K I S M N Y M R K G Q 356

1084 ACA GTT AAA ATC AAA GCT GCT GAT GAA GAT AAA ATT GCT TCT TCA GTT CAA TTG CTG CAA 1143
357 T V K I K A A D E D K I A S S V Q L L Q 376

1144 TTC CCA AAA CGC TCA GAA TAT CCA CCT GAA GCT GAA TGG GTT ACA GTT CAA GAA TTA GTT 1203
377 F P K R S E Y P P E A E W V T V Q E L V 396

1204 TTT AAC GAT GAA ACT AAT TAT GTT CCA GTT TTG GAG CTT GCT TAC ATA GAA GAT TCT GAT 1263
397 F N D E T N Y V P V L E L A Y I E D S D 416

1264 GGA AAA TAT TGG GTT GTA CAG CAA AAC GTT CCA ACT GTA GAA AGA GTA GAT TCT TTA AAT 1323
417 G K Y W V V Q Q N V P T V E R V D S L N 436

1324 GAT TCT ACT AGA GCA AGA TTA GGC GTA ATT GCT TTA GCT ACA CAA GCT CAA GCT AAT GTC 1383
437 D S T R A R L G V I A L A T Q A Q A N V 456

1384 GAT TTA GAA AAT TCT CCA CAA AAA GAA TTA GCA ATT ACT CCA GAA ACG TTA GCT AAT CGT 1443
457 D L E N S P Q K E L A I T P E T L A N R 476

1444 ACT GCT ACA GAA ACT CGC AGA GGT ATT GCA AGA ATA GCA ACT ACT GCT CAA GTG AAT CAG 1503
477 T A T E T R R G I A R I A T T A Q V N Q 496

```

FIG. 7

8471-005 (SHEET 13 OF 19)

T4 Genes 34-37 seq -> Genes

```

1504 AAC ACC ACA TTC TCT TTT GCT GAT GAT ATT ATC ATC ACT CCT AAA AAG CTG AAT GAA AGA 1563
497 N T T F S F A D D I I I T P K K L N E R 516

1564 ACT GCT ACA GAA ACT CGT AGA GGT GTC GCA GAA ATT GCT ACG CAG CAA GAA ACT AAT GCA 1623
517 T A T E T R R G V A E I A T Q Q E T N A 536

1624 GGA ACC GAT GAT ACT ACA ATC ATC ACT CCT AAA AAG CTT CAA GCT CGT CAA GGT TCT GAA 1683
537 G T D D T T I I T P K K L Q A R Q G S E 556

1684 TCA TTA TCT GGT ATT GTA ACC TTT GTA TCT ACT GCA GGT GCT ACT CCA GCT TCT AGC CGT 1743
557 S L S G I V T F V S T A G A T P A S S R 576

1744 GAA TTA AAT GGT ACG AAT GTT TAT AAT AAA AAC ACT GAT AAT TTA GTT GTT TCA CCT AAA 1803
577 E L N G T N V Y N K N T D N L V V S P K 596

1804 GCT TTG GAT CAG TAT AAA GCT ACT CCA ACA CAG CAA GGT GCA GTA ATT TTA GCA GTT GAA 1863
597 A L D Q Y K A T P T Q Q G A V I L A V E 616

1864 AGT GAA GTA ATT GCT GGA CAA AGT CAG CAA GGA TGG GCA AAT GCT GTT GTA ACG CCA GAA 1923
617 S E V I A G Q S Q G W A N A V V T P E 636

1924 ACG TTA CAT AAA AAG ACA TCA ACT GAT GGA AGA ATT GGT TTA ATT GAA ATT GCT ACG CAA 1983
637 T L H K A K T S T D G R I G L I E I A T Q 656

1984 AGT GAA GTT AAT ACA GGA ACT GAT TAT ACT CGT GCA GTC ACT CCT AAA ACT TTA AAT GAC 2043
657 S E V N T G T D Y T R A V T P K T L N D 676

2044 CGT AGA GCA ACT GAA AGT TTA AGT GGT ATA GCT GAA ATT GCT ACA CAA GTT GAA TTC GAC 2103
677 R R A T E S L S G I A E I A T Q V E F D 696

2104 GCA GGC GTC GAC GAT ACT CGT ATC TCT ACA CCA TTA AAA ATT AAA ACC AGA TTT AAT AGT 2163
697 A G V D D T R I S T P L K I K T R F N S 716

2164 ACT GAT CGT ACT TCT GTT GTT GCT CTA TCT GGA TTA GTT GAA TCA GGA ACT CTC TGG GAC 2223
717 T D R T S V V A L S G L V E S G T L W D 736

2224 CAT TAT ACA CTT AAT ATT CTT GAA GCA AAT GAG ACA CAA CGT GGT ACA CTT CGT GTA GCT 2283
737 H Y T L N I L E A N E T Q R G T L R V A 756

2284 ACG CAG GTC GAA GCT GCT GCG GGA ACA TTA GAT AAT GTT TTA ATA ACT CCT AAA AAG CTT 2343
757 T Q V E A A A G T L D N V L I T P K K L 776

2344 TTA GGT ACT AAA TCT ACT GAA GCG CAA GAG GGT GTT ATT AAA GTT GCA ACT CAG TCT GAA 2403
777 L G T K S T E A Q E G V I K V A T Q S E 796

2404 ACT GTG ACT GGA ACG TCA GCA AAT ACT GCT GTA TCT CCA AAA AAT TTA AAA TGG ATT GCG 2463
797 T V T G T S A N T A V S P K N L K W I A 816

2464 CAG AGT GAA CCT ACT TGG GCA GCT ACT ACT GCA ATA AGA GGT TTT GTT AAA ACT TCA TCT 2523
817 Q S E P T W A A T T A I R G F V K T S S 836

2524 GGT TCA ATT ACA TTC GTT GGT AAT GAT ACA GTC GGT TCT ACC CAA GAT TTA GAA CTG TAT 2583
837 G S I T F V G N D T V G S T Q D L E L Y 856

2584 GAG AAA AAT AGC TAT GCG GTA TCA CCA TAT GAA TTA AAC CGT GTA TTA GCA AAT TAT TTG 2643
857 E K N S Y A V S P Y E L N R V L A N Y L 876

2644 CCA CTA AAA GCA AAA GCT GCT GAT ACA AAT TTA TTG GAT GGT CTA GAT TCA TCT CAG TTC 2703
877 P L K A K A A D T N L L D G L D S S Q F 896

2704 ATT CGT AGG GAT ATT GCA CAG ACG GTT AAT GGT TCA CTA ACC TTA ACC CAA CAA ACG AAT 2763
897 I R R D I A Q T V N G S L T L T Q Q T N 916

2764 CTG AGT GCC CCT CTT GTA TCA TCT AGT ACT GGT GAA TTT GGT GGT TCA TTG GCC GCT AAT 2823
917 L S A P L V S S S T G E F G S L A A N 936

2824 AGA ACA TTT ACC ATC CGT AAT ACA GGA GCC CCG ACT AGT ATC GTT TTC GAA AAA GGT CCT 2883
937 R T F T I R N T G A A P T S I V F E K G P 956

2884 GCA TCC GCG GCA AAT CCT GCA CAG TCA ATG AGT ATT CGT GTA TGG GGT AAC CAA TTT GGC 2943
957 A S G A N P A Q S H S I R V W G N Q F G 976

2944 GGC GGT AGT GAT ACG ACC CGT TCG ACA GTG TTT GAA GTT GGC GAT GAC ACA TCT CAT CAC 3003
977 G G S D T T R S T V F E V G D D T S H H 996

3004 TTT TAT TCT CAA CGT AAT AAA GAC GGT AAT ATA GCG TTT AAC ATT AAT GGT ACT GTA ATG 3063
997 F Y S Q R N K D G N I A F N I N G T V H 1016

3064 CCA ATA AAC ATT AAT GCT TCC GGT TTG ATG AAT GTG AAT GGC ACT GCA ACA TTC GGT CGT 3123
1017 P I N I N A S G L H N V N G T A T F G R 1036

3124 TCA GTT ACA GCC AAT GGT GAA TTC ATC AGC AAG TCT GCA AAT GCT TTT AGA GCA ATA AAC 3183
1037 S V T A N G E F I S K S A N A F R A I N 1056

```

FIG. 7 (CONT.)

8471-005 (SHEET 14 OF 19)

T4 Genes 34-37 seq -> Genes

3184 GGT GAT TAC GGA TTC TTT ATT CGT AAT GAT GCC TCT AAT ACC TAT TTT TTG CTC ACT GCA 3243
1057 G D Y G F F I R N D A S N T Y F L L T A 1076

3244 GCC GGT GAT CAG ACT GGT GGT TTT AAT GGA TTA CGC CCA TTA TTA ATT AAT AAT CAA TCC 3303
1077 A G D Q T G G F N G L R P L L I N N Q S 1096

3304 GGT CAG ATT ACA ATT GGT GAA GGC TTA ATC ATT GCC AAA GGT GTT ACT ATA AAT TCA GGC 3363
1097 G Q I T I G E G L I I A K G V T I N S G 1116

3364 GGT TTA ACT GTT AAC TCG AGA ATT CGT TCT CAG GGT ACT AAA ACA TCT GAT TTA TAT ACC 3423
1117 G L T V N S R I R S Q G T K T S D L Y T 1136

3424 CGT GCG CCA ACA TCT GAT ACT GTA GGA TTC TGG TCA ATC GAT ATT AAT GAT TCA GCC ACT 3483
1137 R A P T S D T V G F W S I D I N D S A T 1156

3484 TAT AAC CAG TTC CCG GGT TAT TTT AAA ATG GTT GAA AAA ACT AAT GAA GTG ACT GGG CTT 3543
1157 Y N Q F P G Y F K M V E K T N E V T G L 1176

3544 CCA TAC TTA GAA CGT GGC GAA GAA GTT AAA TCT CCT GGT ACA CTG ACT CAG TTT GGT AAC 3603
1177 P Y L E R G E V K S P G T L T Q F G N 1196

3604 ACA CTT GAT TCG CTT TAC CAA GAT TGG ATT ACT TAT CCA ACG ACG CCA GAA GCG CGT ACC 3663
1197 T L D S L Y Q D W I T Y P T T P E A R T 1216

3664 ACT CGC TGG ACA CGT ACA TGG CAG AAA ACC AAA AAC TCT TGG TCA AGT TTT GTT CAG GTA 3723
1217 T R W T R T W Q K T K N S W S S F V Q V 1236

3724 TTT GAC GGA GGT AAC CCT CCT CAA CCA TCT GAT ATC GGT GCT TTA CCA TCT GAT AAT GCT 3783
1237 F D G G N P P Q P S D I G A L P S D N A 1256

3784 ACA ATG GGG AAT CTT ACT ATT CGT GAT TTC TTG CGA ATT GGT AAT GTT CGC ATT GTT CCT 3843
1257 T M G N L T I R D F L R I G N V R I V P 1276

3844 GAC CCA GTG AAT AAA ACG GTT AAA TTT GAA TGG GTT GAA TAA GAGGTATT ATC GAA AAA TTT 3905
1277 D P V N K F E V E * M E K F 4

3906 ATG GCC GAG ATT TGG ACA AGG ATA TGT CCA AAC GCC ATT TTA TCG GAA AGT AAT TCA GTA 3965
5 M A E I W T R I C P N A I L S E S N S V 24

3966 AGA TAT AAA ATA AGT ATA GCG GGT TCT TGC CCG CTT TCT ACA GCA GGA CCA TCA TAT GTT 4025
25 R Y K I S I A G S C P L S T A G P S Y V 44

4026 AAA TTT CAG GAT AAT CCT GTA GGA AGT CAA ACA TTT AGG CGC AGG CCT TCA TTT AAG AGT 4085
45 K F Q D N P V G S Q T F R R R P S F K S 64

4086 TTT TGA CCCTTCCACCGGAGCATTAGTTGATAGTAAGTCAT ATG CTT TTT CGA CTT CAA ATG ATA CTA 4153
65 F * M L F R L Q M I L 9

4154 CAT CAG CTG CTT TTG TTA GTT TTC ATG AAT TCT TTG ACG AAT AAT CGA ATT GTT GCT ATA 4213
10 H Q L L L L V F M N S L T N N R I V A I 29

4214 TTA ACT AGT GGA AAG GTT AAT TTT CCT CCT GAA GTA GTA TCT TGG TTA AGA ACC GCC GGA 4273
30 L T S G K V N F P P E V V S W L R T A G 49

4274 ACG TCT GCC TTT CCA TCT GAT TCT ATA TTG TCA AGA TTT GAC GTA TCA TAT GCT GCT TTT 4333
50 T S A F P S D S I L S R F D V S Y A A F 69

4334 TAT ACT TCT TCT AAA AGA GCT ATC GCA TTA GAG CAT GTT AAA CTG AGT AAT AGA AAA AGC 4393
70 Y T S S K R A I A L E H V K L S N R K S 89

4394 ACA GAT GAT TAT CAA ACT ATT TTA GAT GTT GTA TTT GAC AGT TTA GAA GAT GTA GGA GCT 4453
90 T D D Y Q T I L D V V F D S L E D V G A 109

4454 ACC GGG TTT CCA AGA AGA ACG TAT GAA AGT GTT GAG CAA TTC ATG TCG GCA GTT GGT GGA 4513
110 T G F P R R T Y E S V E Q F H S A V G G 129

4514 ACT AAT AAC GAA ATT GCG AGA TTG CCA ACT TCA GCT GCT ATA AGT AAA TTA TCT GAT TAT 4573
130 T N N E I A R L P T S A A I S K L S D Y 149

4574 AAT TTA ATT CCT GGA GAT GTT CTT TAT CTT AAA GCT CAG TTA TAT GCT GAT GCT GAT TTA 4633
150 N L I P G D V L Y L K A Q L Y A D A D L 169

4634 CTT GCT CTT GGA ACT ACA AAT ATA TCT ATC CGT TTT TAT AAT GCA TCT AAC GGA TAT ATT 4693
170 L A L G T T N I S I R F Y N A S N G Y I 189

4694 TCT TCA ACA CAA GCT GAA TTT ACT GCG CAA GCT GCG TCA TGG GAA TTA AAG GAA GAT TAT 4753
190 S S T Q A E F T G G Q A G S W E L K E D Y 209

4754 GTA GTT GTT CCA GAA AAC GCA GTA GGA TTT ACG ATA TAC GCA CAG AGA ACT GCA CAA GCT 4813
210 V V V P E N A V G F T I Y A Q R T A Q A 229

FIG. 7 (CONT.)

8471-005 (SHEET 15 OF 19)

T4 Genes 34-37 seq -> Genes

4814 GGC CAA GGT GGC ATG AGA AAT TTA AGC TTT TCT GAA GTA TCA AGA AAT GGC GGC ATT TCG 4873
230 G Q G G M R N L S F S E V S R N G I S 249

4874 AAA CCT GCT GAA TTT GGC GTC AAT GGT ATT CGT GTT AAT TAT ATC TGC GAA TCC GCT TCA 4933
250 K P A E F G V N G I R V N Y I C E S A S 269

4934 CCT CCG GAT ATA ATG GTA CTT CCT ACG CAA GCA TCG TCT AAA ACT GGT AAA GTG TTT GGG 4993
270 P P D I H V L P T Q A S S K T G K V F G 289

4994 CAA GAA TTT AGA GAA GTT TAA ATTGAGGGACCGTTCGGGTTCCTTTTCTTTTATAAAATACTATTCAAATAAA 5066
290 Q E F R E V * 296

5067 GGGGCATACA ATG GCT GAT TTA AAA GTA GGT TCA ACA ACT GGA GGC TCT GTC ATT TGG CAT 5127
1 M A D L K V G S T T G G S V I W H 17

5128 CAA GGA AAT TTT CCA TTG AAT CCA GCC GGT GAC GAT GTA CTC TAT AAA TCA TTT AAA ATA 5187
18 Q G N F P L N P A G D D V L Y K S F K I 37

5188 TAT TCA GAA TAT AAC AAA CCA CAA GCT GCT GAT AAC GAT TTC GTT TCT AAA GCT AAT GGT 5247
38 Y S E Y N K P Q A A D N D F V S K A N G 57

5248 GGT ACT TAT GCA TCA AAG GTA ACA TTT AAC GCT GGC ATT CAA GTC CCA TAT GCT CCA AAC 5307
58 G T Y A S K V T F N A G F Q V P Y A P N 77

5308 ATC ATG AGC CCA TGC GGG ATT TAT GGG GGT AAC GGT GAT GGT GCT ACT TTT GAT AAA GCA 5367
78 I M S P C G I Y G G N G D G A T F D K A 97

5368 AAT ATC GAT ATT GTT TCA TGG TAT GGC GTA GGA TTT AAA TCG TCA TTT GGT TCA ACA GGC 5427
98 N I D I V S W Y G V G F K S S F G S T G 117

5428 CGA ACT GTT GTA ATT AAT ACA CGC AAT GGT GAT ATT AAC ACA AAA GGT GTT GTG TCG GCA 5487
118 R T V V I N T R N G D I N T K G V V S A 137

5488 GCT GGT CAA GTA AGA AGT GGT GCG GCT GCT CCT ATA GCA GCG AAT GAC CTT ACT AGA AAG 5547
138 A G Q V R S G A A A P I A A N D L T R K 157

5548 GAC TAT GTT GAT GGA GCA ATA AAT ACT GTT ACT GCA AAT GCA AAC TCT AGG GTG CTA CGG 5607
158 D Y V D G A I N T V T A N A N S R V L R 177

5608 TCT GGT GAC ACC ATG ACA GGT AAT TTA ACA GCG CCA AAC TTT TTC TCG CAG AAT CCT GCA 5667
178 S G D T M T G N L T A G P N F F S Q N P A 197

5668 TCT CAA CCC TCA CAC GTT CCA CGA TTT GAC CAA ATC GTA ATT AAG GAT TCT GTT CAA GAT 5727
198 S Q P S H V P R F D Q I V I K D S V Q D 217

5728 TTC GGC TAT TAT TAA GAGGACTT ATG GCT ACT TTA AAA CAA ATA CAA TTT AAA AGA AGC AAA 5789
218 F G Y Y * M A T L K Q I Q F K R S K 13

5790 ATC GCA GGA ACA CGT CCT GCT GCT TCA GTA TTA GCC GAA GGT GAA TTG GCT ATA AAC TTA 5849
14 I A G T R P A A S V L A E G E L A I N L 33

5850 AAA GAT AGA ACA ATT TTT ACT AAA GAT GAT TCA GGA AAT ATC ATC GAT CTA GGT TTT GCT 5909
34 K D R T I F T K D D S G N I I D L G F A 53

5910 AAA GGC GGG CAA GTT GAT GGC AAC GTT ACT ATT AAC GGA CTT TTG AGA TTA AAT GGC GAT 5969
54 K G G Q V D G N V T I N G L L R L N G D 73

5970 TAT GTA CAA ACA GGT GGA ATG ACT GTA AAC GGA CCC ATT GGT TCT ACT GAT GGC GTC ACT 6029
74 Y V Q T G G M T V N G P I G S T D G V T 93

6030 GGA AAA ATT TTC AGA TCT ACA CAG GGT TCA TTT TAT GCA AGA GCA ACA AAC GAT ACT TCA 6089
94 G K I F R S T Q G S F Y A R A T N D T S 113

6090 AAT GCC CAT TTA TGG TTT GAA AAT GCC GAT GGC ACT GAA CGT GGC GTT ATA TAT GCT CGC 6149
114 N A H L W F E N A D G T E R G V I Y A R 133

6150 CCT CAA ACT ACA ACT GAC GGT GAA ATA CGC CTT AGG GTT AGA CAA GGA ACA GGA AGC ACT 6209
134 P Q T T T D G E I R L R V R Q G T G S T 153

6210 GCC AAC AGT GAA TTC TAT TTC CGC TCT ATA AAT GGA GGC GAA TTT CAG GCT AAC CGT ATT 6269
154 A N S E F Y F R S I N G G E F Q A N R I 173

6270 TTA GCA TCA GAT TCG TTA GTA ACA AAA CGC ATT GCG GTT GAT ACC GTT ATT CAT GAT GCC 6329
174 L A S D S L V T K R I A V D T V I H D A 193

6330 AAA GCA TTT GGA CAA TAT GAT TCT CAC TCT TTG GTT AAT TAT GTT TAT CCT GGA ACC GGT 6389
194 K A F G Q Y D S H S L V N Y V Y P G T G 213

6390 GAA ACA AAT GGT GTA AAC TAT CTT CGT AAA GTT CGC GCT AAG TCC GGT GGT ACA ATT TAT 6449
214 E T N G V N Y L R K V R A K S G G T I Y 233

6450 CAT GAA ATT GTT ACT GCA CAA ACA GGC CTG GCT GAT GAA GTT TCT TGG TGG TCT GGT GAT 6509
234 H E I V T A Q T G L A D E V S W W S G D 253

FIG. 7 (CONT.)

8471-005 (SHEET 16 OF 19)

T4 Genes 34-37 seq -> Genes

```

6510 ACA CCA GTA TTT AAA CTA TAC GGT ATT CGT GAC GAT GGC AGA ATG ATT ATC CGT AAT AGC 6569
254 T P V F K L Y G I R D D G R M I I R N S 273
6570 CTT GCA TTA GGT ACA TTC ACT ACA AAT TTC CCG TCT AGT GAT TAT GGC AAC GTC GGT GTA 6629
274 L A L G T F T T N F P S S D Y G N V G V 293
6630 ATG GGC GAT AAG TAT CTT GTT CTC GGC GAC ACT GTA ACT GGC TTG TCA TAC AAA AAA ACT 6689
294 M G D K Y L V L G D T V T G L S Y K K T 313
6690 GGT GTA TTT GAT CTA GTT GGC GGT GGA TAT TCT GTT GCT TCT ATT ACT CCT GAC AGT TTC 6749
314 G V F D L V G G G Y S V A S I T P D S F 333
6750 CGT AGT ACT CGT AAA GGT ATA TTT GGT CGT TCT GAG GAC CAA GGC GCA ACT TGG ATA ATG 6809
334 R S T R K G I F G R S E D Q G A T W I M 353
6810 CCT GGT ACA AAT GCT GCT CTC TTG TCT GTT CAA ACA CAA GCT GAT AAT AAC AAT GCT GGA 6869
354 P G T N A A L L S V Q T Q A D N N N A G 373
6870 GAC GGA CAA ACC CAT ATC GGG TAC AAT GCT GGT AAA ATG AAC CAC TAT TTC CGT GGT 6929
374 D G Q T H I G Y N A G G K M N H Y F R G 393
6930 ACA GGT CAG ATG AAT ATC AAT ACC CAA CAA GGT ATG GAA ATT AAC CCG GGT ATT TTG AAA 6989
394 T G Q M N I N T Q Q G M E I N P G I L K 413
6990 TTG GTA ACT GGC TCT AAT AAT GTA CAA TTT TAC GCT GAC GGA ACT ATT TCT TCC ATT CAA 7049
414 L V T G S N N V Q F Y A D G T I S S I Q 433
7050 CCT ATT AAA TTA GAT AAC GAG ATA TTT TTA ACT AAA TCT AAT AAT ACT GCG GGT CTT AAA 7109
434 P I K L D N E I F L T K S N N T A G L K 453
7110 TTT GGA GCT CCT AGC CAA GTT GAT GGC ACA AGG ACT ATC CAA TGG AAC GGT GGT ACT CGC 7169
454 F G A P S Q V D G T R T I Q W N G G T R 473
7170 GAA GGA CAG AAT AAA AAC TAT GTG ATT ATT AAA GCA TGG GGT AAC TCA TTT AAT GCC ACT 7229
474 E G Q N K N Y V I I K A W G N S F N A T 493
7230 GGT GAT AGA TCT CGC GAA ACG GTT TTC CAA GTA TCA GAT AGT CAA GGA TAT TAT TTT TAT 7289
494 G D R S R E T V F Q V S D S Q G Y Y F Y 513
7290 GCT CAT CGT AAA GCT CCA ACC GGC GAC GAA ACT ATT GGA CGT ATT GAA GCT CAA TTT GCT 7349
514 A H R K A P T G D E T I G R I E A Q F A 533
7350 GGG GAT GTT TAT GCT AAA GGT ATT ATT GCC AAC GGA AAT TTT AGA GTT GTT GGG TCA AGC 7409
534 G D V Y A K G I I A N G N F R V V G S S 553
7410 GCT TTA GCC GGC AAT GTT ACT ATG TCT AAC GGT TTG TTT GTC CAA GGT GGT TCT TCT ATT 7469
554 A L A T M N V T M S N G L F V Q G S S I 573
7470 ACT GGA CAA GTT AAA ATT GGC GGA ACA GCA AAC GCA CTG AGA ATT TGG AAC GCT GAA TAT 7529
574 T G Q V K I G G T A N A L R I W N A E Y 593
7530 GGT GCT ATT TTC CGT CGT TCG GAA AGT AAC TTT TAT ATT ATT CCA ACC AAT CAA AAT GAA 7589
594 G A I F R R S E S N F Y I I P T N Q N E 613
7590 GGA GAA AGT GGA GAC ATT CAC AGC TCT TTG AGA CCT GTG AGA ATA GGA TTA AAC GAT GGC 7649
614 G E S G D I H S S L R P V R I G L N D G 633
7650 ATG GTT GGG TTA GGA AGA GAT TCT TTT ATA GTA GAT CAA AAT AAT GCT TTA ACT ACG ATA 7709
634 M V G L G R D S F I V D Q N N A L T T I 653
7710 AAC AGT AAC TCT CGC ATT AAT GCC AAC TTT AGA ATG CAA TTG GGG CAG TCG GCA TAC ATT 7769
654 N S N S R I N A N F R M Q L G Q S A Y I 673
7770 GAT GCA GAA TGT ACT GAT GCT GTT CGC CCG GCG GGT GCA GGT TCA TTT GCT TCC CAG AAT 7829
674 D A E C T D A V R P A G A G S F A S Q N 693
7830 AAT GAA GAC GTC CGT GCG CCG TTC TAT ATG AAT ATT GAT AGA ACT GAT GCT AGT GCA TAT 7889
694 N E D V R A P F Y M N I D R T D A S A Y 713
7890 GTT CCT ATT TTG AAA CAA CGT TAT GTT CAA GGC AAT GGC TCG TAT TCA TTA GGG ACT TTA 7949
714 V P I L K Q R Y V Q G N G C Y S L G T L 733
7950 ATT AAT AAT GGT AAT TTC CGA GTT CAT TAC CAT GGC GGC GGA GAT AAC GGT TCT ACA GGT 8009
734 I N N G N F R V H Y G G G D N G S T G 753
8010 CCA CAG ACT GCT GAT TTT GGA TGG GAA TTT ATT AAA AAC GGT GAT TTT ATT TCA CCT CGC 8069
754 P Q T A D F G W E F I K N G D F I S P R 773
8070 GAT TTA ATA GCA GGC AAA GTC AGA TTT GAT AGA ACT GGT AAT ATC ACT GGT GGT TCT GGT 8129
774 D L I A G K V R F D R T G N I T G G S G 793

```

FIG. 7 (CONT.)

8471-005 (SHEET 17 OF 19)

T4 Genes 34-37 seq -> Genes

```

8130 AAT TTT GCT AAC TTA AAC AGT ACA ATT GAA TCA CTT AAA ACT GAT ATC ATG TCG AGT TAC 8189
794 N F A N L N S T I E S L K T D I M S S Y 813
8190 CCA ATT GGT GCT CCG ATT CCT TGG CCG AGT GAT TCA GTT CCT GCT GGA TTT GCT TTG ATG 8249
814 P I G A P I P W P S D S V P A G F A L M 833
8250 GAA GGT CAG ACC TTT GAT AAG TCC GCA TAT CCA AAG TTA GCT GTT GCA TAT CCT AGC GGT 8309
834 E G Q T F D K S A Y P K L A V A Y P S G 853
8310 GTT ATT CCA GAT ATG CCG GGG CAA ACT ATC AAG GGT AAA CCA AGT GGT CGT GCT GTT TTG 8369
854 V I P D M R G Q T I K G K P S G R A V L 873
8370 AGC GCT GAG GCA GAT GGT GTT AAG GCT CAT AGC CAT AGT GCA TCG GCT TCA AGT ACT GAC 8429
874 S A E A D G V K A H S H S A S A S S T D 893
8430 TTA GGT ACT AAA ACC ACA TCA AGC TTT GAC TAT GGT ACG AAG GGA ACT AAC AGT ACG GGT 8489
894 L G T K T T S S P D Y G T K G T N S T G 913
8490 GGA CAC ACT CAC TCT GGT AGT GGT TCT ACT AGC ACA AAT GGT GAG CAC AGC CAC TAC ATC 8549
914 G H T H S G S G S T N G E H S H Y I 933
8550 GAG GCA TGG AAT GGT ACT GGT GTA GGT GGT AAT AAG ATG TCA TCA TAT GCC ATA TCA TAC 8609
934 E A W N G T G V G G N K M S S Y A I S Y 953
8610 AGG GCG GGT GGG AGT AAC ACT AAT GCA GCA GGG AAC CAC AGT CAC ACT TTC TCT TTT GGG 8669
954 R A G G S N T N A A G N H S H T F S F G 973
8670 ACT AGC AGT GCT GGC GAC CAT TCC CAC TCT GTA GGT ATT GGT GCT CAT ACC CAC ACG GTA 8729
974 T S S A G D H S H S V G I G A H T H T V 993
8730 GCA ATT GGA TCA CAT GGT CAT ACT ATC ACT GTA AAT AGT ACA GGT AAT ACA GAA AAC ACG 8789
994 A I G S H G H T I T V N S T G N T E N T 1013
8790 GTT AAA AAC ATT GCT TTT AAC TAT ATC GTT CGT TTA GCA TAA GGAGAGGGGGCTTCGGCCCTTCTAA 8855
1014 V K N I A F N Y I V R L A * 1027

```

FIG. 7 (CONT.)




FIG. 8A



FIG. 8B



FIG. 9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/13023

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/195; C12P 21/06; C07H 17/00

US CL : 530/300, 350; 435/69.1, 69.7; 536/23.1, 23.4, 23.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 350; 435/69.1, 69.7; 536/23.1, 23.4, 23.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Science, Vol. 254, issued 29 November 1991, D.H. Freedman, "Exploiting the nanotechnology of life", pages 1308-1310, see entire document.	1-53
A	Science, Vol. 254, issued 29 November 1991, G.M. Whitesides et al., "Molecular self-assembly and nanochemistry: A chemical strategy for the synthesis of nanostructures", pages 1312-1319, see entire document.	1-53
A	Genetics, Vol. 94, issued March 1980, J.N. Levy et al., "Region-specific recombination in phage T4. II. Structure of the recombinants", pages 531-547, see entire document.	1-53

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 16 JANUARY 1996	Date of mailing of the international search report 01 FEB 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Karen Cochrane Carlson, Ph.D. Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/13023

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. Mol. Biol., Vol. 132, issued 1979, W.C. Earnshaw et al., "The distal half of the tail fibre of bacteriophage T4 rigidly linked domains and cross- β structure", pages 101-131, see entire document.	1-53

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

